Latest / CME Outfitters Medical Education / Case Closed? Diagnosing Idiopathic Hypersomnia Beyond the Usual Suspects
Transcript
- 0:01SPEAKER_09: Hello, I'm Dr.
- 0:02SPEAKER_09: Emory Morse.
- 0:03SPEAKER_09: I'm a neurologist with special qualifications in child neurology and pediatric sleep medicine as well as adult sleep medicine.
- 0:10SPEAKER_09: And I'm very excited on behalf of CME Outfitters to welcome you to today's educational activity that is called Case Closed, Diagnosing Idiopathic Hypersomnia Beyond the Usual Suspects.
- 0:23SPEAKER_09: And so you may be saying who's the usual suspect because of the fact that we recognize that there really is no usual when you're talking about central disorders of hypersomnolence.
- 0:33SPEAKER_09: Each person very frequently is going to have their own journey.
- 0:36SPEAKER_09: I would like to acknowledge our educational partner, the Hypersomnia Foundation, with whom we collaborate to develop this activity.
- 0:43SPEAKER_02: This activity may include discussions of products or devices that are not currently labeled for use by the U.S.
- 0:50SPEAKER_02: Food and Drug Administration.
- 0:53SPEAKER_02: The faculty have been informed of their responsibility to disclose if they will be discussing off-label or investigational uses during this activity.
- 1:05SPEAKER_02: Our presenting faculty panel today also includes Dr.
- 1:08SPEAKER_02: David Plant and Maggie Lavender.
- 1:12SPEAKER_02: In addition, throughout this activity, we have integrated the perspectives of three contributing key opinion leaders, Dr.
- 1:20SPEAKER_02: John Carter, Dr.
- 1:21SPEAKER_02: Eve Daubier, and Dr.
- 1:24SPEAKER_02: Kieran Maskey, as well as three patient advocates, Caitlin Dilley, Becky Gabony, and Haley Wall.
- 1:33SPEAKER_09: The majority of our time will be spent working through two patient cases, each reflecting common but challenging situations you encounter in real-world practice.
- 1:42SPEAKER_09: These cases will include patient perspectives, community clinician voices, KOL videos, AOI responses, and expert faculty commentary.
- 1:52SPEAKER_09: You'll see brief video and audio segments throughout the program.
- 1:56SPEAKER_09: The session is designed to be highly interactive.
- 1:59SPEAKER_02: Our learning objectives for this activity include one, evaluate the latest efficacy and safety data for current and emerging therapies for patients with IH.
- 2:11SPEAKER_02: Two, integrate appropriate guideline, recommended diagnostic criteria, and comprehensive assessments into practice when there is clinical suspicion of IH to improve early and accurate diagnosis.
- 2:26SPEAKER_02: Three, identify the nature of overlapping symptoms of IH and other hypersomnia disorders.
- 2:35SPEAKER_02: We will begin today with a discussion about the idiopathic hypersomnia landscape, including disease burden diagnostic frameworks, and both approved and investigational therapies.
- 2:48SPEAKER_02: To start, let's dive into some compelling statistics related to both delayed as well as missed diagnosis of idiopathic hypersomnia.
- 2:58SPEAKER_06: But it takes so long to figure out what is going on and appropriately diagnose it.
- 3:02SPEAKER_06: 60% of patients with IH are initially misdiagnosed.
- 3:07SPEAKER_06: 69% experience greater than one year of a delay to get to diagnosis, and about 20% wait 10 or more years to accurately diagnose it.
- 3:17SPEAKER_06: What are we missing?
- 3:18SPEAKER_06: IH is commonly misattributed to mood disorders.
- 3:21SPEAKER_06: It's confused with other central disorders of hypersomnia, especially narcolepsy type 2, inefficient sleep syndrome.
- 3:28SPEAKER_06: We must have a great detailed diagnostic workup to rule out all of these other things and make sure we're narrowing in on the true patient symptoms.
- 3:36SPEAKER_06: Delayed diagnosis is not only detrimental to the patient, but it impairs their daily life, their quality of living.
- 3:44SPEAKER_06: It causes a common burden.
- 3:46SPEAKER_06: They just can't think clearly through the day.
- 3:48SPEAKER_06: It causes work and school disruption.
- 3:50SPEAKER_06: They're there, but they're cognitively not there.
- 3:53SPEAKER_06: So their productivity is down.
- 3:55SPEAKER_06: And of course, all of this leads to a reduced quality of life.
- 4:00SPEAKER_09: So I think when we're looking at this, we're very clearly seeing a pattern that is not a new pattern.
- 4:06SPEAKER_09: We've been having this conversation about narcolepsy for how many years?
- 4:10SPEAKER_09: And now we're seeing that we're having a very similar challenge.
- 4:13SPEAKER_09: When you're talking about idiopathic hypersomnia, when we're looking at a diagnosis that already is burdened by the name idiopathic hypersomnia, it is going to be strong to having challenges.
- 4:23SPEAKER_09: And when you're looking at the epidemiology of idiopathic hypersomnia, it was only first described in 1956 by Bendrick Long, where he was first describing the concepts of sleep drunkens.
- 4:36SPEAKER_09: Since that time, it has undergone almost 12 different either suggested or actual nomenclature.
- 4:45SPEAKER_09: With that state, it very frequently is getting missed, masked, and misdiagnosed.
- 4:52SPEAKER_09: So the best way to illustrate this is really going to be by a patient advocate who's going to describe what the consequence of that may look like.
- 5:01SPEAKER_11: I really was not given diagnoses along the way.
- 5:06SPEAKER_11: As I tried to seek out answers, it just was like not acknowledged.
- 5:11SPEAKER_11: And not, you know, like it was almost like a doctor would take a first step to appease me because I had brought it up.
- 5:17SPEAKER_11: And the other thing, you know, that I think plays out here is that when someone's dealing with a sleep disorder and has that little energy and like time to to address something, it's really hard to advocate for yourself within the healthcare system.
- 5:33SPEAKER_11: And so it was exhausting to me, you know, to create to carve out time to go to the doctor um and get and try to get answers.
- 5:44SPEAKER_11: And so when I kept not getting answers and not getting any closer to some kind of diagnosis or explanation or something, um, it was really exhausting and and became quite a barrier.
- 5:56SPEAKER_11: So I um I was really not given a diagnosis um you know, all the way through until just recently when I started um receiving treatment.
- 6:10SPEAKER_11: And in a way that feels um gaslighting is such a buzzword right now.
- 6:20SPEAKER_11: But it's it's like am I crazy for thinking that this is abnormal?
- 6:28SPEAKER_11: Because I'm telling doctors and they don't seem they don't seem to have any concern with it.
- 6:34SPEAKER_11: And so I'm like having this debilitating experience that I'm trying to manage through and I'm suffering, like absolutely suffering.
- 6:42SPEAKER_11: But the people who are the experts don't seem to have like a sense of urgency around it.
- 6:49SPEAKER_11: For my sense of self, I think it just it it became very confusing on something that felt like so uh impactful and burdensome to me, seemed to be so so unconcerning to the medical community.
- 7:02SPEAKER_09: When you hear the story that was just described, uh and I'm gonna throw this to you first, David.
- 7:08SPEAKER_09: How frequently do you encounter that?
- 7:10SPEAKER_09: And I would say that maybe uh either as a first opinion or the person who's diagnosing, or even maybe as a second or third opinion of that I had seen all these different doctors, they told me there was nothing wrong with me.
- 7:22SPEAKER_09: I had all the blood tests that were right, I had all the imaging that was right, I had the EEG that was right, and so how can everything be right and I still be so wrong?
- 7:31SPEAKER_09: What how does that show up in your clinic?
- 7:34SPEAKER_01: I think it shows up in different ways.
- 7:35SPEAKER_01: Uh people have different experiences and journeys getting there.
- 7:38SPEAKER_01: A lot of times I'm a psychiatrist by original training, so a lot of patients come to me sort of funneled through psychiatric clinics, um, where again they may have had blood work hopefully to rule out sort of different common causes, but people don't really know exactly what to do.
- 7:51SPEAKER_01: And I think the other challenge is people don't always know what to ask.
- 7:54SPEAKER_01: Uh so they sort of get caught in these what I call sort of whirlpools, right?
- 7:58SPEAKER_01: That's how to really slow down their journey down uh the river.
- 8:01SPEAKER_01: So I think they can come from all the different clinics, and uh the key I think is just asking the right questions and believing the patient too and sort of what they're expressing.
- 8:09SPEAKER_01: I think I feel hard.
- 8:11SPEAKER_01: I mean I I tear up a little bit thing about like some of the feeling that they're gaslit by their position.
- 8:15SPEAKER_01: That's never the intent.
- 8:17SPEAKER_09: But I also understand the the desire to have an objective finding or something that can point to the disease or disorder, because a lot of people don't think about how I with that, Maggie, I'm gonna hand you over the microphone for us to be able to go through some of these approved and key emerging trials.
- 8:34SPEAKER_06: So looking into the future, it's right.
- 8:36SPEAKER_06: We have many coming.
- 8:38SPEAKER_06: So the first one is going to be the once-nightly sodium oxalate extended release, and this is already FDA approved for cataplexy and EDS with adults with narcolepsy as of 23.
- 8:49SPEAKER_06: Um, but we're looking into phase three trials for adults with IH.
- 8:54SPEAKER_06: Then on the horizon is all of our erxin agonists.
- 8:58SPEAKER_06: Up front, we have Lorexin.
- 9:00SPEAKER_06: It's in phase two under the Vibrant 3 study.
- 9:03SPEAKER_06: Um it's on an ongoing study looking for the approval for adult AIH, and hopefully we get that approved any day now.
- 9:11SPEAKER_06: Um then we're looking at TAC 360, and then we're looking at erecin 750 with additional erection angonist right behind it in phase two 1A.
- 9:21SPEAKER_06: So as we continue, let's look at the one that is already approved.
- 9:24SPEAKER_06: So we're looking at um low sodium um oxybase in phase three adult IH.
- 9:28SPEAKER_06: So, how is this approved?
- 9:30SPEAKER_06: It was a phase three multi-center, placebo controlled double blind, randomized withdrawal study.
- 9:35SPEAKER_06: Um, so what happened is we had um 10 weeks, and then for um 14 weeks it was an open open label titration optimization period.
- 9:44SPEAKER_06: Then we stabilized them for two weeks.
- 9:46SPEAKER_06: Um, and then what happened?
- 9:48SPEAKER_06: The inclusion was that we had patients for 18 between 18 and 75 years old with a diagnosis of IH.
- 9:55SPEAKER_06: Okay, um, 154 patients were enrolled, but we ended up using 115 randomized due to modification for intention to treat population.
- 10:04SPEAKER_06: We measured the change in ESS from the end of the stable dose period to the end of the two-week double blind randomized withdrawal.
- 10:11SPEAKER_06: So they were um titrated and stabilized on their dose.
- 10:14SPEAKER_06: We checked their ESS, we randomized and withdrew the medication and then put them on placebo or continued the medicine, and we measured the ESS again.
- 10:22SPEAKER_06: Um the key endpoints were the patient global impression change scale as well as the um hypersomnia severity scale, and it both favored um low sodium oxidates.
- 10:32SPEAKER_06: Then when you're looking at um your most common side effects, these are not uncommon to us when we're dealing with these oxidates nausea, headache, dizziness, anxiety, and vomiting.
- 10:43SPEAKER_06: Um, no deaths were um in the study, which is amazing.
- 10:47SPEAKER_06: Um the safety signals um are relative to the IH controls and what we already know about the oxidate profile.
- 10:54SPEAKER_06: Um, there is a black box warning, as we know, for CNS depression and abuse and misuse.
- 10:59SPEAKER_06: Um, the regulatory outcome is the FDA approved it in um August of 2021 for the approval of IH with um in adults, and it is the first and only IH-approved medication for adults.
- 11:12SPEAKER_06: If we break down the data a little bit more, and we're looking at the primary and secondary data in the adults.
- 11:17SPEAKER_06: So when we're looking at the ESS score, if you remember, we're looking at it, we had measured it in the comparison once we um regulated their dose, stabilized their dose, and then we with red that randomized withdrawal process.
- 11:28SPEAKER_06: So when we looked at the placebo group after the randomized withdrawal process, their ESS score increased by seven points.
- 11:35SPEAKER_06: When we looked at the ones who continued the low sodium oxidate, there was only a change of 0.7 points in their ESS score.
- 11:41SPEAKER_06: So that clearly shows a difference that it was improving on those patients that continued to get the medication.
- 11:47SPEAKER_06: The secondary endpoint when we're looking at the patient global and questionnaire chain scale, we're looking at the percent that it worsened.
- 11:54SPEAKER_06: Okay.
- 11:54SPEAKER_06: Um so the patients have to answer the question as minimally much or very much worse at the end of the withdrawal period.
- 12:01SPEAKER_06: And quite alarming evidence here on the placebo, they had an 88% um worsening um threshold.
- 12:07SPEAKER_06: And then when they continued on the oxibate, it was a 21.4% there.
- 12:12SPEAKER_06: So when we look at the um one sodium um oxibate extended release, when we're looking at the study design and a glands, we screen them, we put them on the off-label titration, we stabilized them, um, and then we we did the double blind withdrawal.
- 12:25SPEAKER_06: Okay, and then you look at the off-label extension after that.
- 12:29SPEAKER_06: So just as I had explained, the primary endpoint was the change in the ESS score, and then the key secondary endpoints was the patient global impression change scale, the um IHSS score, which is looking at the hypersomnia severity scale, the clinical global impressionary change scale, and then the fosculum.
- 12:47SPEAKER_06: Continuing on, um, again, the design was phase three multi-center double-blind, placebo-controlled randomized withdrawal study.
- 12:54SPEAKER_06: We were looking at a 10-week period open-dose titration, um, and we titrated them from the four and a half grams up to the 10 grams.
- 13:01SPEAKER_06: We stabilized them for those two weeks, and then we did a randomized withdrawal, and then we followed by the open label safety extension.
- 13:08SPEAKER_06: Um, when you look at the population, we had approximately 150 adults between the ages of 18 to 75 with a diagnosis of IH.
- 13:17SPEAKER_06: Um, we had to have an ESS scale score of greater than 11 or 11 and above, which we all know is abnormal.
- 13:23SPEAKER_06: Um, they had to have inclusion of about seven hours of sleep per night at screening, and they could also they could actually be initiating obstacle, transitioning from an existing obstacle as long as we were had been on stabilized dosing, um, and they could be on stimulants and alerting agents as well.
- 13:39SPEAKER_06: Um, the primary endpoint is the change in the ESS score from the end of the open label stable dose as well as after the two-week withdrawal.
- 13:47SPEAKER_06: Um, and then the placebo growth group statistically showed worsening um ESS scores compared to the participants continuing the sodium oxidate.
- 13:56SPEAKER_06: The key secondaries, as again, the patient global impressionary change scale, the hypersomnia severity scale, this is the measure of the functional outcomes of sleep.
- 14:04SPEAKER_06: And of course, it was worsened on the placebo versus the maintenance continuation of the dose.
- 14:08SPEAKER_06: And then we saw that it both worsened significantly on the placebo versus the continued.
- 14:14SPEAKER_06: Again, the most common side effects were nausea, anxiety, headache, dizziness, and vomiting.
- 14:18SPEAKER_06: There were no new safety signals observed in the IH population.
- 14:21SPEAKER_06: Um, we know that it currently carries that black box warning for um CNS depression and um abuse and misuse.
- 14:29SPEAKER_06: And as we know, the once-nightly sodium oxidate extended release has been approved since May of 2023 for cataplexy in adults of narcolepsy um ages seven and above.
- 14:41SPEAKER_06: Um currently it is not approved for IH.
- 14:44SPEAKER_06: Um, the revitalized study is designed to support the potential supplemental indication of IH and enrollment for these studies ended in um December of 2025, and the top one results should be out soon.
- 14:57SPEAKER_06: So currently, the active IH trials that patients can participate in are looking at your erection agonists, which is new, um up and coming.
- 15:06SPEAKER_06: So this is very exciting for this um population.
- 15:09SPEAKER_06: You have Lorexin, which is APS 2680.
- 15:12SPEAKER_06: Um is in the fibrant study, um, is the only named Erexin II agonist with the active dedicated IH efficacy study.
- 15:19SPEAKER_06: Estimated primary completion, like as I said, July of this year in the public top line timing is not confirmed yet.
- 15:26SPEAKER_06: So this should be very near in our future.
- 15:29SPEAKER_06: Then we have TAC 360, possible indication for IH and narcolepsy type 2.
- 15:34SPEAKER_06: It's in its phase two study, and it's looking at active IH, and we're looking at dose signing.
- 15:41SPEAKER_06: Then you have our XM750, and this is another selective agonist, and this is for IH, NT1, and NT2.
- 15:49SPEAKER_06: It's in phase two 1A, and this is the Crystal One study.
- 15:52SPEAKER_06: And this is an IH cohort that is in the early proof of concept crossover study.
- 15:57SPEAKER_09: Before we go to my girl Haley, who she's awesome.
- 16:00SPEAKER_09: She's a woman living with idiopathic hypersomnia.
- 16:02SPEAKER_09: She's also an occupational therapist.
- 16:05SPEAKER_09: And the reason I why I say she's awesome is two years ago, I was speaking at the Beyond CP conference, which is a part of the Hypersomnia Foundation, she came up to me afterwards and said, you know, I am really interested.
- 16:16SPEAKER_09: You had brought up some concepts around how rehab services may be potentially be a part of the treatment landscape for um hypersomnulence disorders.
- 16:27SPEAKER_09: There's no research on it.
- 16:28SPEAKER_09: I really want for us to look at some research on there.
- 16:31SPEAKER_09: So she not only is an advocate and someone who is um uh living with idiopathic hypersomnia, but she's also a person who's looking at how do we change the landscape more holistically.
- 16:41SPEAKER_09: Now, before we go into her story, I just want to kind of again ask um when we're looking at some of these trials that have occurred, right?
- 16:50SPEAKER_09: So we saw the mixed salts oxybate, and this is the first and only medication.
- 16:54SPEAKER_09: What was not presented here was the work that EUWA had done with a double-blind randomized control trial with twice-nightly sodium oxybate, also demonstrating very similar findings from the withdrawal trials, responder profiles by four weeks, lower dosing than what we use in narcolepsy.
- 17:11SPEAKER_09: So, really, again, giving some of this phenotypic distinction.
- 17:15SPEAKER_09: Um and we're now potentially going to hopefully see with revitalize similar.
- 17:21SPEAKER_09: What are your thoughts in regards to the potential future landscape of not only oxybates, but then potentially these erecks and agonists coming to market?
- 17:29SPEAKER_09: Because I think that this really is an exciting period.
- 17:32SPEAKER_09: And where do you think we might see some impact there?
- 17:36SPEAKER_01: Yeah, I think it's a very exciting time in the idiopathic hypersonomy landscape for treatments.
- 17:40SPEAKER_01: I mean, I think just having a singular approved drug is wonderful because it does give, I think, patients access to a lot of opportunities, even uh for trying different medications in the future.
- 17:52SPEAKER_01: I think the paper that you're referring to from Dr.
- 17:55SPEAKER_01: DeVoye is in neurology.
- 17:57SPEAKER_01: Um that study also uh again showed positive benefit of sodium oxabate, and they used maintenance and wakefulness test as well uh in that study.
- 18:05SPEAKER_01: So I think that it's it's probably a potentially a class effect with differences between you know timing and frequency of dosing and things.
- 18:14SPEAKER_01: But again, we have to see the final results from the from the different studies as they come out.
- 18:18SPEAKER_01: And then moving on from oxabates, though, because oxabates are wonderful medications for lots of patients, but not everybody can use or tolerate them.
- 18:25SPEAKER_01: So I think that people, or even respond to them.
- 18:28SPEAKER_01: So I think the more options we have, the better.
- 18:31SPEAKER_01: So I think it's great that the erects and agonists, which are being studied very extensively in type 1 narcolepsy, which is sort of the leading wave, are then also oftentimes being evaluated in other disorders like uh IH and NT2.
- 18:44SPEAKER_08: Before I ever heard the term idiopathic hypersomnia, I always just thought of it as tiredness.
- 18:53SPEAKER_08: And I think that is kind of where the disconnect maybe happened.
- 18:59SPEAKER_08: I was experiencing, I now know, more sleepiness, where I was, you know, actively trying to fight off sleeping, and I was sleeping for prolonged periods, and I just overall felt very fatigued.
- 19:14SPEAKER_08: Um, but I had no idea what idiopathic hypersomia was until the day that I got diagnosed.
- 19:20SPEAKER_08: And that opened up a whole new world of learning and understanding what I was actually going through.
- 19:26SPEAKER_09: So before we get uh to our patient's treatment, we have to first get them diagnosed.
- 19:33SPEAKER_09: So this is where the diagnosis sets the direction.
- 19:38SPEAKER_09: Um, and so when we're seeing that the um IH now has one FDA-approved therapy in adults with additional mechanisms under investigation that include erects and two receptor agonism and even histaminergic wig promotion, um, we really now are seeing that the options are starting to diversify.
- 19:56SPEAKER_09: However, diagnostic mislabeling is even more important to make sure that we're not missing.
- 20:03SPEAKER_09: And also because of the fact that this may lead to some differential use of these medications.
- 20:09SPEAKER_09: So, although we already have them available in narcolepsy, it really is important for us to examine is there a distinction in how we utilize them?
- 20:18SPEAKER_09: So it's really saying we have the tools, but are we now starting to identify that there may be different use cases or how to use them, whether it's in dosing or timing, as David had shared.
- 20:30SPEAKER_09: All right.
- 20:31SPEAKER_09: So this is um where the program really starts to come to life.
- 20:35SPEAKER_09: We're going to review a few conceptual frameworks uh related to identifying idiopathic hypersomnia and its impact on those who are living with the disease.
- 20:44SPEAKER_09: So here we have um a patient case.
- 20:47SPEAKER_09: Uh so David, I'm gonna ask you to kind of uh set the stage on uh why it's important for us to have early and accurate diagnosis.
- 20:56SPEAKER_01: Well, I think the the earlier we can get the diagnosis in place, the faster we can get people treated.
- 21:02SPEAKER_01: That's really the fundamental thing.
- 21:03SPEAKER_01: So this is Elena Brooks.
- 21:05SPEAKER_01: So she's a 29-year-old graduate student and also a part-time laboratory technician.
- 21:09SPEAKER_01: So she's working very hard.
- 21:11SPEAKER_01: And over the last 12 to 18 months, she's been having a persistent sleepiness, difficulty waking up, fatigue, um, and really problems with concentrating and poor performance at work and at school.
- 21:23SPEAKER_01: So the challenge is she's she's sleeping quite a bit.
- 21:26SPEAKER_01: She's sleeping nine to ten hours on weeknights, and then on the weekends, she sleeps even more up to 12 hours.
- 21:31SPEAKER_01: She still is unrefreshed regardless of how much sleep she gets.
- 21:35SPEAKER_01: And in the morning, she sets multiple alarms, um, and then it really takes her quite a bit of time until she feels sort of reasonably awake in the morning, so up to 90 minutes.
- 21:46SPEAKER_01: And then also during the day, when she's awake, she never really feels fully there.
- 21:49SPEAKER_01: She has pervasive mental fogs, slowed processing, uh, and she's really struggling uh in the lab to get her work done and also to keep up with school.
- 21:58SPEAKER_01: And then on top of that, she'll take Unplanned naps uh that just sort of happen, and when they happen they're quite prolonged.
- 22:03SPEAKER_01: They can be an hour to two hours.
- 22:06SPEAKER_01: And again, naps are also not restorative for her.
- 22:08SPEAKER_01: And that's despite she's tried using caffeine, but it doesn't really do much of anything.
- 22:14SPEAKER_01: And and then in terms of like her other history that might be relevant, she doesn't have a substance use history, she doesn't shift work, shift, work.
- 22:21SPEAKER_01: Um her primary care provider was a little bit flummoxed and decided, well, perhaps you're depressed, so prescribed 50 milligrams, well, sergaline that was titrated up to 50 milligrams, and really after 10 weeks hadn't really done anything in terms of any sort of impact on symptoms.
- 22:36SPEAKER_01: And then she was still tired and feeling like she just like was never fully on as the way she describes some of her symptoms.
- 22:42SPEAKER_01: And she was quite frustrated, which is similar, I think, to some of the patients that we've heard sort of talk about the challenges with getting a diagnosis.
- 22:50SPEAKER_01: And a lot of a provider were saying, well, this might be stress, this might be burnout, or or potentially mood related.
- 22:55SPEAKER_01: And she's really frustrated.
- 22:57SPEAKER_01: She's trying to get a diagnostic plan and sort of have some realistic expectations around that.
- 23:02SPEAKER_09: So this sounds a lot like that that first patient video that we had seen of that I went to different people, um, uh they weren't able to come to an answer, at least in this particular case, it sounds like the primary care was trying to utilize an antidepressants.
- 23:17SPEAKER_09: David, as a psychiatrist, how does that strike you?
- 23:20SPEAKER_09: When you see this kind of story, what would you say to a primary care or even maybe a sleep medicine specialist who is going to be inheriting this patient as a referral?
- 23:30SPEAKER_09: Of what parts of this would be red flags for you of this may not be depression?
- 23:36SPEAKER_01: Well, I think the first part and sort of absent from the vignette is depression, right?
- 23:41SPEAKER_01: So technically to have major depressive disorder, you have to have depressed mood or anhedonia.
- 23:46SPEAKER_01: So there are a lot of overlapping neurovegetative symptoms that can occur in both major depressive disorder and idiopathic hypersomnia.
- 23:55SPEAKER_01: So fatigue, low energy.
- 23:56SPEAKER_01: You can also have hypersomnia as part of a depressive episode as well.
- 24:00SPEAKER_01: So there's there can be overlap.
- 24:01SPEAKER_01: But again, if someone's not complaining that they are depressed, that's your first warning, I think, to say maybe this isn't depression.
- 24:09SPEAKER_01: But I also understand that uh depression is a much more common condition than IH.
- 24:14SPEAKER_01: So it makes sense that people may wonder, oh, well, perhaps this person is depressed.
- 24:17SPEAKER_01: I mean, it makes sense, but again, I would I would want to know more about the depression and potentially anhedonia.
- 24:23SPEAKER_09: Yeah.
- 24:23SPEAKER_09: So what I'm hearing there is to exercise caution when someone says, I just can't get out of bed.
- 24:30SPEAKER_09: I just can't do things.
- 24:32SPEAKER_09: I just have no desire to do those things.
- 24:36SPEAKER_09: That hearing knows it it does strike the cord of depression, right?
- 24:40SPEAKER_09: And it's not uncommon that that on the flip side of this, when a person gets appropriately diagnosed and treated and they're having improved symptoms, they very frequently will say, I never actually had depressed symptoms.
- 24:54SPEAKER_09: I was really more frustrated, upset that I knew I had the capabilities to do the things, or I didn't have the energy to do the things.
- 25:05SPEAKER_09: Which is, I think, a really important distinction because as a job of a clinician, we're really trained to kind of take what people are saying and funnel it into buckets of differentials.
- 25:15SPEAKER_09: And just as you stated, David, uh depression is a very common one, and we don't typically reach for the hypersomnance disorders or sleep disorders in general that very well can masquerade around like a hypersomnolence disorder.
- 25:30SPEAKER_09: Now, when looking at this laboratory mood screening, why don't you make a few comments in regards to what you make of what you're seeing here?
- 25:39SPEAKER_01: So again, the the PHQ9, for example, for those of you who aren't familiar, is a very useful screening tool for depression.
- 25:46SPEAKER_01: And it ended up in a in a mild range.
- 25:48SPEAKER_01: And another thing that you can do is sort of to kind of harken back to what I was talking about with the mood and anxiety symptoms, you can even boil it down to the PHQ.
- 25:57SPEAKER_01: Uh, and if that score is not elevated, but the pH Q9 is even, in this case, mildly elevated, it makes you wonder do they really have uh depression?
- 26:05SPEAKER_01: Um, other things, I think this is a good sort of start for a workup to make sure that people aren't anemic, to make sure that they're uh not hypothyroidism.
- 26:13SPEAKER_01: My experience has been a lot of patients with IH have had their TSH checked like 10 times in the hopes that maybe that they have hypothyroidism, but they don't, right?
- 26:21SPEAKER_01: Um Ferritin's a little bit tricky because uh the the patient she hadn't been complaining about restless leg syndrome.
- 26:28SPEAKER_01: Of course, if she were, that's a very important lab value to check.
- 26:31SPEAKER_01: Um, but also sometimes people can have sort of subclinical or anemia as well.
- 26:35SPEAKER_01: And then off uh I live in Wisconsin, so you know, vitamin low vitamin D is not uncommon, so it's important to check.
- 26:42SPEAKER_01: But here again, it was pretty normal.
- 26:44SPEAKER_01: So Yeah.
- 26:46SPEAKER_09: Um, Maggie, what uh any additional labs that you sometimes think about um that aren't listed on here that you also just like to make sure to exclude in regards to uh some mimics of idiopathic hypersomnia?
- 26:58SPEAKER_06: I think the labs are pretty much covered.
- 27:00SPEAKER_06: The big one for me is always ruling out is there anything else that could be disrupting their sleep?
- 27:05SPEAKER_06: So they're sleeping for many hours, um, but is it quality sleep?
- 27:08SPEAKER_06: So we always go after your major disruptors.
- 27:11SPEAKER_06: So looking at the ferritin and ruling out, even though the patient is not complaining of a rust um situation or their bed partner's not complaining that they're moving often, is their little rhythmic twitches that are happening that could be causing the arousal factor.
- 27:23SPEAKER_06: Um, and then we have to pose the question and concern of are we having any um increased effort of breathing or sleep disorder breathing that we need to rule out?
- 27:31SPEAKER_06: Because we can't just go off of only your daytime symptoms.
- 27:34SPEAKER_06: We have to look at other potential causes and ruling out nighttime problems is a really big one.
- 27:38SPEAKER_09: Yeah.
- 27:39SPEAKER_09: I would say the only other thing that I very commonly encounter in terms of labs, so I see kids and adults, and I live in central Pennsylvania, the Lyme capital of the world.
- 27:49SPEAKER_09: Um and so uh it's not uncommon that uh I see Lyme testing, and sometimes there's varied interpretations of what the Lime testing is.
- 28:00SPEAKER_09: Um and that sometimes gets to mislabeling.
- 28:03SPEAKER_09: The other thing that I see very commonly is Epstein Barr virus, and it's not uncommon that I'll see maybe those late teens, college-age kiddos where the EBV IgG is positive, but there was never any history of mono.
- 28:21SPEAKER_09: Um and there is no IgM that's positive, and that sometimes gets anchored too, of that it must just be a chronic uh result of mono.
- 28:31SPEAKER_09: So um those I think are are all really important things to look at as well.
- 28:34SPEAKER_06: You can go down the path of you know discovering if there's a mold issue too, but then that opens up a whole bunch of things, and that's kind of a very long pathway, but you can pose those questions as well.
- 28:46SPEAKER_09: So, David, take us through some of these um medications and what the relevance may be in in relation to your your workup for Alana.
- 28:55SPEAKER_01: Well, she the only thing that she's on is search line.
- 28:58SPEAKER_01: So that actually makes it a little bit easier.
- 29:00SPEAKER_01: Sometimes patients come to us on a whole slew of medications.
- 29:03SPEAKER_01: Um search line is gonna have in her case, it wasn't helpful, so potentially why is she on it?
- 29:09SPEAKER_01: Um, right?
- 29:10SPEAKER_01: And then but if she were to stay on it, for example, it's gonna have pretty significant problems in terms of our potential workup when we think about sleep testing.
- 29:18SPEAKER_01: Because we know that SSRIs really do a number on polycenography, right?
- 29:24SPEAKER_01: They tend to suppress REM.
- 29:25SPEAKER_01: So if we're looking and doing an MSLT, it can affect those results there.
- 29:29SPEAKER_01: But it also causes other sometimes people will have you know periodic limb movements of sleep resulting from an SSRI, and then that can lead you down to some sort of wild goose chases.
- 29:39SPEAKER_01: If they're not associated with arousals and you just have a number of PLMs, there's a question of, well, maybe this person has PLMD.
- 29:45SPEAKER_01: So, you know, ideally what I always say is if you don't need the medication, let's get you off of it, right?
- 29:51SPEAKER_01: Um, in terms of other medications, um, uh she's not on hypnotics.
- 29:56SPEAKER_01: Sometimes people will come to us on benzodiazepines for other reasons, for anxiety disorders and things like that.
- 30:02SPEAKER_01: Obviously, they're really tricky to sort of unwind whether the sleepiness is related to a compound that certainly can be sedating.
- 30:09SPEAKER_01: She's not on opioids, um, she's not on stimulants at this point either.
- 30:14SPEAKER_01: Um, it's important, I think, in the history, sort of we didn't get in the vignette of whether or not there was a history of head trauma.
- 30:21SPEAKER_01: Uh, and if so, was that related to the the onset of sleepiness?
- 30:24SPEAKER_01: Because certainly we can see post-traumatic hypersomas occur.
- 30:28SPEAKER_01: And then cataplexy is really important to ask about.
- 30:31SPEAKER_01: Usually ask about it in a couple of different ways if you can.
- 30:34SPEAKER_01: Um, but it because if we heard that she had cataplexy, if that she had loss of muscle tone in response to emotional stimuli, that would certainly change potentially the diagnostic equation, the way that we might evaluate her or think about her, as we would have a much higher suspicion that she'd have potentially type one narcolepsy.
- 30:52SPEAKER_09: Yeah, I mean, if she had a history of cataplexy, if she has greater than three months of excessive daytime sleepiness, you can use your psychiatry book, the DSM5TR, right, um to establish a diagnosis without any um uh testing, right?
- 31:04SPEAKER_09: Um uh now with that stated, um uh this is an idiopathic hypersomnia talk.
- 31:10SPEAKER_09: So the chances are she doesn't have narcolepsy.
- 31:12SPEAKER_09: Now, with that stated, we've had a couple of questions that have come in.
- 31:16SPEAKER_09: Uh, and one of them would be would management change if patient was on puproprion as opposed to surrellene?
- 31:22SPEAKER_09: What are your thoughts about that?
- 31:25SPEAKER_01: Well, I I would say yes and no.
- 31:28SPEAKER_01: You got him excited.
- 31:29SPEAKER_01: Good job.
- 31:30SPEAKER_01: So I mean, buproprium is commonly used as so it's an antidepressant, but it's not particularly serotonergic.
- 31:36SPEAKER_01: It also tends to help a little bit more with fatigue and potentially sleepiness.
- 31:41SPEAKER_01: So I would say if the primary care doctor had started her on that, I would say kudos, you know, you're for trying that, because maybe that would be more likely to impact the symptoms.
- 31:50SPEAKER_01: That means they probably listened more to the symptoms and were trying a treatment.
- 31:54SPEAKER_01: But again, I would say, are you getting benefit from this, right?
- 31:57SPEAKER_01: So if you're not getting benefit from it, do you really need it?
- 32:00SPEAKER_01: Now the other thing is in theory, buproprion shouldn't cause a lot of the same problems on PSGs that we see with SSRIs, uh, like um uh affecting REM sleep.
- 32:11SPEAKER_01: I think it's an open discussion about how much buproprion affects the MSLT mean sleep latency, to be completely honest with you.
- 32:18SPEAKER_01: From my perspective, there isn't data.
- 32:20SPEAKER_01: So what I usually do is if a patient is on that medication for co-occurring depression, but I still want to get an MSLT, I'll have a frank discussion with them and say, do you think that we could get you off of this?
- 32:30SPEAKER_01: These are the pluses and minuses of being on it, and then sort of take it on a case-by-case basis.
- 32:35SPEAKER_09: Well, you actually um uh just brought up the other question I was going to ask.
- 32:40SPEAKER_09: You responded more specifically for prepoprion, but very frequently a question I get asked by um uh many clinicians is if I have a patient who I can't take off of the antidepressant, or you name the drug that may interfere, um uh do I still go through with it?
- 32:59SPEAKER_09: Because I've heard many, many patients tell me, I can't, my doctor told me I can't have an MSLT because I'm on an antidepressant, and I go.
- 33:08SPEAKER_01: Yeah, I mean what I would say is it's a it's a different risk-benefit decision for each patient, and really it should be a collaborative decision.
- 33:16SPEAKER_01: So sort of explaining to what I try to do is explain to the patients, here are the if we could get if we can't get you off the medications, here's what might happen.
- 33:23SPEAKER_01: We might not be able to text sleep onset REM periods.
- 33:26SPEAKER_01: So your diagnosis may be a little bit you know, questioned, we may not know, but certainly if it's I wouldn't take someone off of a medication and make them unsafe for it for a test, right?
- 33:37SPEAKER_01: I think, and that's where people can give you an idea of how likely they are.
- 33:41SPEAKER_01: I mean, it can I I've seen it go both ways.
- 33:42SPEAKER_01: Some patients tell me straight up, like, there's no way I can go off my antidepressant.
- 33:46SPEAKER_01: It would put me in danger.
- 33:48SPEAKER_01: And absolutely, I mean, psychiatric conditions are life-threatening in many cases.
- 33:52SPEAKER_01: So there I'm like, we're not gonna touch it.
- 33:54SPEAKER_01: We can still do the testing, we'll just live with the results and interpret it as needed.
- 33:58SPEAKER_01: Then there are some patients who are like, well, yeah, like in this case, my doctor put me on this.
- 34:02SPEAKER_01: I don't know if I really need it, or maybe they were on it for a long time and they wonder, can I go off it?
- 34:08SPEAKER_01: So I say, okay, well, maybe now's a good time to try.
- 34:10SPEAKER_01: Uh and so it's you know, tapering people off in advance of the testing, I think, can be really helpful in those cases, if possible.
- 34:17SPEAKER_09: So two other questions that have come in that have some overlap include um, what about B12 or methamalonic acid?
- 34:25SPEAKER_09: Are you checking these out?
- 34:27SPEAKER_09: Um what are your what are your thoughts around that?
- 34:29SPEAKER_01: I was gonna say that is a test that I usually get if it hasn't been obtained somewhere else.
- 34:33SPEAKER_01: And in the history, I'll also ask, you know, one, do you eat a diet that includes animal products, right?
- 34:38SPEAKER_01: There's a lot of people who are vegan uh and they're gonna be at increased risk for B12 deficiency.
- 34:43SPEAKER_01: I will also, in terms of other labs that I may consider, I will sometimes get an anti-nuclear antibody because I've seen cases where sort of these sort of the symptom constellations of fatigue and sleepiness kind of precede a rheumatologic condition uh as well that's sometimes sort of missed in general work.
- 35:00SPEAKER_01: And then the only other thing that I'll sometimes think about is again checking uh a sed rate, even though it's very nonspecific.
- 35:06SPEAKER_01: If it's very elevated, it makes you wonder like, is there something else going on that potentially we're missing?
- 35:11SPEAKER_01: Because it really shouldn't be elevated uh in IH.
- 35:15SPEAKER_01: Peggy, any additional thoughts on that?
- 35:17SPEAKER_06: Um the only other thought is this slide mostly paid attention to prescription agents.
- 35:22SPEAKER_06: Um we have to really hone in and question have they tried to dose themselves with any over-the-counters or herbals or anything like that?
- 35:28SPEAKER_06: So really getting a good clean-cut history of what are they self-medicating with that has worked or has not worked in the past or could be contributing to their symptoms as well.
- 35:37SPEAKER_09: Yeah, like like alcohol, right?
- 35:39SPEAKER_09: Um uh and then um uh when you're taking patients off of medication, how long do you typically um ask for them to be off of it before the test?
- 35:49SPEAKER_01: Well, I think it really depends on the medication and the half-life, right?
- 35:54SPEAKER_01: So for most SSRIs, ideally people will be off of it, like done with the taper two weeks before the test.
- 36:02SPEAKER_01: But uh fluoxetine is the one that has the usually the biggest caveat because it has an extraordinarily long half-life.
- 36:09SPEAKER_01: So usually you probably want to be off of that medication ideally six to eight weeks.
- 36:13SPEAKER_01: So that can be quite a deal breaker for people because it has an active metabolite even that's still there for a long time.
- 36:18SPEAKER_01: So that one is it's easy to taper off of.
- 36:21SPEAKER_01: That's the good news, right?
- 36:22SPEAKER_01: But the bad news is uh it takes a long time to get out of the system.
- 36:26SPEAKER_09: Any specific comments about venlofaxine and being that some patients can have withdrawal from it?
- 36:32SPEAKER_01: Uh sure.
- 36:33SPEAKER_01: Yes, so venlofaxine is a tricky one.
- 36:36SPEAKER_01: Some people can It's good to have a psychiatrist.
- 36:39SPEAKER_01: Some people can get off venilfaxine, I think, relatively without too much difficulty, but for some people they really do get stuck.
- 36:45SPEAKER_01: I remember when I was a resident, I had a patient who had tried three times to get off of venilofaxine unsuccessfully.
- 36:52SPEAKER_01: So we spent a year tapering her off of venlofaxcine incredibly slowly.
- 36:56SPEAKER_01: Um I wouldn't expect that we would that would be done for uh you know, to before it I wouldn't say that if it took a year to get off medication, we shouldn't do an MSLT at that point because that might just delay it further.
- 37:07SPEAKER_09: Yeah.
- 37:07SPEAKER_01: Just to be clear, I had no concerns that she had a CNS hypersomnia.
- 37:10SPEAKER_01: Um, but in that case, what some tricks are to get the immediate release formulation and take just keep cutting the dose as much as possible and getting the dose as low and low as possible before you step off.
- 37:22SPEAKER_01: So there are some tricks to getting people off of that medication, but it can be tricky.
- 37:25SPEAKER_01: Yeah.
- 37:26SPEAKER_09: So just a couple of things that I would add comments on from the lab perspective is that with B12, as a neurologist, most typically I consider abnormal less than 400 because it can produce neurologic symptoms.
- 37:37SPEAKER_09: The lab will usually have a cutoff of 200.
- 37:39SPEAKER_09: The other component is if you're not familiar with the literature of elevated B12s, uh B12s over a thousand repeated twice in a year are signals of uh patients at risk for increased mortality and many times maybe related to cancers and oncologic processes.
- 37:55SPEAKER_09: And so that becomes important because cancer can make you sleepy too.
- 37:59SPEAKER_09: Um, and those are things that you definitely don't want to miss.
- 38:02SPEAKER_09: Uh so another one is that a great question would be differentiating fatigue versus excessive daytime sleepiness.
- 38:10SPEAKER_09: And while we chat about that a bit, we are gonna move on to an audience polling.
- 38:15SPEAKER_09: Um, and so with the audience polling, one of the things to know is the great part about this is it's a poll, not a quiz.
- 38:21SPEAKER_09: So there's no right answer.
- 38:22SPEAKER_09: It's really trying to understand are we kind of evaluating what might be things that we can do?
- 38:28SPEAKER_09: So, which initial assessment approach most appropriately clarifies whether her symptoms reflect IH, a primary mood disorder, insufficient sleep?
- 38:54SPEAKER_09: So the majority had said administered up worth, initiate a two-week sleep diary with ectigraphy, and reassess the symptom cluster, including prolonged uh sleep time, severe sleep inertia, and unrefreshing.
- 39:06SPEAKER_09: Um uh so I I I what what do you guys say about that?
- 39:09SPEAKER_09: I think that that's a really great response.
- 39:11SPEAKER_09: I think if if I were to uh respond, I would probably say that I would I'd probably do that one and then also refer directly to overnight PhD followed by uh next day MSLT, and that's just because it's gonna be six months before they get into that.
- 39:24SPEAKER_09: So I can collect this information in the meantime and I can always cancel it out if I need to.
- 39:28SPEAKER_09: What about you guys?
- 39:29SPEAKER_09: Anything else?
- 39:31SPEAKER_01: You know, I think the other thing to think about is like using other screening tools in Clinic, like the IHSS.
- 39:36SPEAKER_01: I think it's actually a pretty useful tool.
- 39:38SPEAKER_01: I use it a fair amount.
- 39:40SPEAKER_01: I I actually struggle.
- 39:41SPEAKER_01: You know, I think they design the questions intentionally to be a little bit tricky because I like to get the IHSS ideally after sort of the testing as well, um, but it's a useful tool uh to obtain that.
- 39:54SPEAKER_09: Wonderful.
- 39:55SPEAKER_09: Um so the patient voice, what patients need clinicians to hear?
- 40:00SPEAKER_09: And so this actually is getting to uh the point around the excessive daytime sleepiness versus uh fatigue issue.
- 40:08SPEAKER_09: So um, David, I want you to walk us through this slide, but also if you can comment a bit on the distinction the distinction, the distinction between um excessive daytime sleepiness and fatigue.
- 40:19SPEAKER_01: Sure.
- 40:19SPEAKER_01: So this was a survey that sort of uh from patients like telling us kind of what we should be doing.
- 40:25SPEAKER_01: So what I would say first of all is it's not always easy to distinguish fatigue from being sleepy.
- 40:31SPEAKER_01: I think many of us as sleep conditions spend a lot of our time trying to figure that out.
- 40:35SPEAKER_01: And people will often say, I mean, I think the most common complaint or chief complaint I should say that people present with is, I'm tired of being tired.
- 40:44SPEAKER_01: So right off the bat, when people are saying they're tired, you have to untangle, like, what does that mean?
- 40:49unknown: Right?
- 40:49SPEAKER_01: So what how are you experiencing that?
- 40:51SPEAKER_01: So I think that you know it's important to keep in mind that when people say they're tired, they may also be experiencing daytime sleepiness, right?
- 40:59SPEAKER_01: So it's important to try to get at those particular symptoms.
- 41:02SPEAKER_01: And are you having trouble staying awake?
- 41:04SPEAKER_01: What kind of situations do you not off in, et cetera?
- 41:06SPEAKER_01: And I think it's really important because um if you think that it's just fatigue, for example, it's just different from daytime sleepness, then you're going to miss some of the problems because these patients tend to have you know trouble staying awake or also never feeling fully awake.
- 41:21SPEAKER_01: Um, and then the the majority of folks will also say it's really hard to get out of bed or even with alarms.
- 41:26SPEAKER_01: So a lot of times people don't ask about sleep inertia in the typical histories.
- 41:30SPEAKER_01: They may ask, what time do you go to bed, what time you wake up, how long does it take you to fall asleep, etc.
- 41:35SPEAKER_01: But they don't ask about sort of how they feel when they first awaken, and if it is impaired, how long does that take?
- 41:40SPEAKER_01: Um also I think they want to sort of call out that oftentimes the wrong diagnosis comes first, right?
- 41:47SPEAKER_01: Which to a certain degree is understandable.
- 41:49SPEAKER_01: This is a complex situation where you do have to rule out a number of different things first, and there may be other sort of symptoms or mimics that or disorders that mimic the condition that you have to think about.
- 42:00SPEAKER_01: But it's it's more common that people are told that it's depression, stress, or burnout or those kinds of things.
- 42:06SPEAKER_01: And then also another thing that comes up is providers to say, well, just get more sleep.
- 42:10SPEAKER_01: You must be tired, you must be because you're not sleeping enough.
- 42:14SPEAKER_01: The reality is these folks are telling their doctors, actually, I'm sleeping longer if the doctors ask the questions.
- 42:20SPEAKER_01: The doctors may not ask how long they're even sleeping.
- 42:22SPEAKER_01: And then again, another point they bring up is the diagnostic journey is very hard to navigate.
- 42:26SPEAKER_01: Um, this came up a lot in the patient vignettes.
- 42:30SPEAKER_01: Um and then sort of what came up over and over again is the idea of barriers, right?
- 42:34SPEAKER_01: So barriers of getting a referral to a sleep specialist who understood the disorder, barriers to knowing how to for they themselves to describe the symptoms to people, and then barriers also in terms of like coming up with a treatment plan or something that actually works for them.
- 42:48SPEAKER_01: And then sort of what would have helped for them, the things that sort of tend to be expressed were like, again, sort of us as clinicians asking more targeted questions about these symptoms, like how hard is it to wake up, how like what kind of are you having naps, are they refreshing, brain fog, excessive sleep time, et cetera.
- 43:05SPEAKER_01: And then also more clear education, ex under explaining to patients why IH is different from depression.
- 43:14SPEAKER_01: And then also people felt like a uh symptom uh checklist or daily diary or tracking tool might be helpful for them as well.
- 43:23SPEAKER_09: So how how when we look at this is what patients are hoping that their clinicians are starting to understand and describing it, how does this correlate with some of the functional impact that we're seeing with idiopathic hypersomnia?
- 43:37SPEAKER_01: Yeah, so this is data from the Arise trial, um, which is a survey based data, but they also completed various questionnaires.
- 43:43SPEAKER_01: And so what this slide really shows, and I think highlights, is the level of impairment that patients with IH can have.
- 43:48SPEAKER_01: So there's pretty clear impacts on daily function.
- 43:51SPEAKER_01: And I think when you sort of look at the way that the scale breaks down, so there is absenteeism, but it's not as dramatic.
- 43:58SPEAKER_01: So people show up to Work oftentimes, like they get there, but their presenteism, their ability to actually like engage in their work is severely impaired, right?
- 44:07SPEAKER_01: And then when you even when you combine absenteeism and presenteism, that's how these scales sort of look at overall work, productivity, impairment, it's quite profound, right?
- 44:16SPEAKER_01: But it's not because people don't make it to work, it's usually they may be tardy, but they they are not fully present.
- 44:21SPEAKER_01: And then the overall activity is also quite impaired.
- 44:24SPEAKER_09: Yeah, and I always like to remind people that over$400 billion a year is lost in the workplace due to sleep disorders.
- 44:31SPEAKER_09: So asking questions like this can actually be quite productive across sleep disorders.
- 44:36SPEAKER_09: The other component that I would just say is that this also is a nice distinguishment from narcolepsy.
- 44:41SPEAKER_09: Um and so when you're looking at idiopathic hypersomnia, they have low absenteeism.
- 44:46SPEAKER_09: Because of the lack of predictability with narcolepsy, they tend to have high absenteeism.
- 44:51SPEAKER_09: Um, and the presenteism many times also is reflecting that brain fog phenomena.
- 44:56SPEAKER_09: And they typically aren't coming in, at least I haven't had patients come in and go, you know, Doctor, I have very poor presenteism at work.
- 45:04SPEAKER_09: Um they usually are saying I'm getting yelled at a lot at work, I'm missing assignments, I feel like I'm just kind of spacing out, um, and that's impairing my ability to work.
- 45:15SPEAKER_09: And so when you start to hear these patterns, you can start to see why we present data like this.
- 45:21SPEAKER_09: But most typically people aren't explaining the data in a way that you're hearing it in clinic, because we're all hearing it.
- 45:27SPEAKER_09: It's this that we're people aren't utilizing the words about absenteeism or presenteism.
- 45:33SPEAKER_09: And it becomes really important to understand those patterns so you can appropriate recognize them.
- 45:39SPEAKER_09: So, David, in regards to some core epidemiology and uh patient burden, can you give us a little bit more insight in regards to this?
- 45:47SPEAKER_01: Yeah, so there's there is work on the sort of the prevalence of idiopathic hypersonomy.
- 45:55SPEAKER_01: It's a really challenging thing to study, though, because really a lot of the work depends on claims-based data, which relies that the diagnosis be made in the first place.
- 46:03SPEAKER_01: So that's a very important caveat to keep in mind.
- 46:06SPEAKER_01: So um, when we're looking at the diagnosed prevalence of IH, it's it's relatively low.
- 46:10SPEAKER_01: It's a rare condition in that case.
- 46:12SPEAKER_01: It's about 10.5 to 12 per 100,000, depending on the claims data set and how far you look back.
- 46:18SPEAKER_01: It can go up a little bit higher to like 33 to 49 for 100,000 cases if you go back, you know, all like across all larger data sets.
- 46:27SPEAKER_01: Um we have some data from the Wisconsin State Cohort study that we published actually that suggests, though, the true prevalence may be quite a bit higher.
- 46:34SPEAKER_01: So there's probably a number of people out there who are not identified or diagnosed.
- 46:39SPEAKER_01: Um in terms of the age of onset, so classically, this tends to be a disorder that presents like in adolescence, young adulthood, and there's a lot of other stuff going on in people's lives at that time.
- 46:50SPEAKER_01: So that can sometimes lead to sort of misattribution of the symptoms to other stuff, right?
- 46:56SPEAKER_01: So um either stress, schoolwork, uh maybe mood disorder, the brooding teenager, those kinds of things.
- 47:02SPEAKER_01: So that can really delay the diagnosis.
- 47:05SPEAKER_01: And again, the delayed diagnosis is sort of unfortunately more the um rule than the exception.
- 47:10SPEAKER_01: Uh so it takes, you know, uh at least uh 61% have a uh a misdiagnosis, which will delay treatment.
- 47:19SPEAKER_01: And then in terms of how long it takes to get uh diagnosed, it's at least a year for the vast majority of people.
- 47:24SPEAKER_01: And like to almost 20% of people, it takes over 10 years to get diagnosed.
- 47:29SPEAKER_01: It can take a long, long time.
- 47:30SPEAKER_01: And again, there's a whole host of these whirlpools that can kind of suck people in and delay their their journey that we've already uh touched on it quite a bit.
- 47:38SPEAKER_01: And we've talked about the functional impacts a bit with the Arise study.
- 47:41SPEAKER_01: It can be quite uh impairing, but it's so that's one of the reasons that patients, I think, come to us and they're looking for help, and by the time they get to us are uh sometimes desperate for attention.
- 47:53SPEAKER_01: Um and then the symptom profile, again, it's be more than just daytime sleepiness in these folks, oftentimes, although daytime sleepiness is certainly a core symptom of the disorder.
- 48:03SPEAKER_01: Again, the excessive sleep inertia can be quite impairing for people.
- 48:07SPEAKER_01: Uh, it can certainly lead to like being tardy for work and those kinds of things, and all kinds of routines that have to be in place that really use up a lot of time and energy for the waking day.
- 48:17SPEAKER_01: And then also people will often sleep long amounts of time.
- 48:20SPEAKER_01: So, I mean, I tell people to sort of to try to imagine feeling sleepy during the day and only having like 12 hours of functional awake time to get all the things that you have to do done in your life.
- 48:29SPEAKER_01: So it's really, really challenging and can be impairing for folks.
- 48:33SPEAKER_09: Wonderful.
- 48:34SPEAKER_09: Um and so let's go quickly through the um foundational framework so we can return back to our patients.
- 48:40SPEAKER_09: So, David, can you take us through this quickly so we can uh get back to Alan?
- 48:44SPEAKER_09: She's been waiting a long time to do that.
- 48:45SPEAKER_01: So the the ICSD3 uh just had its text revision, but the basically the main things is you have to have to have the diagnosis are a complaint of daytime sleepiness, right?
- 48:55SPEAKER_01: You shouldn't have cataplexy.
- 48:57SPEAKER_01: On the multiple sleep latency tests, you should have a mean sleep latency less than or equal to eight minutes and should have less than two SORAMs, including the overnight polysomnogram.
- 49:05SPEAKER_01: Um and then also another way to make the diagnosis, at least using objective findings, is to use a 24-hour sleep diagnostic like an overnight PSG that's extended, although those can be hard to do clinically, or actigraphy with a sleep log average over at least seven days.
- 49:20SPEAKER_01: You should really make sure that you rule out insufficient sleep syndrome because that's going to be a very common cause of daytime sleepiness, although history should help guide that, but it's good to corroborate that ideally with ectigraphy.
- 49:33SPEAKER_01: And then typically, again, the hypersomnalus shouldn't be due to some other factor that you're able to identify, like a sleep disorder, circadian rhythm disorder, medical disorder, etc.
- 49:42SPEAKER_09: Just because I think this is an important concept, and I always think if you come to see me, it should be things that impact your clinical work.
- 49:49SPEAKER_09: Um, some other workarounds, because I'll see yet an insurance company, I'll pay for a 24-hour polysnography, but they'll pay for a 24-hour EEG or ambulatory EEG.
- 49:59SPEAKER_09: You just have to connect with your neurologist to make sure you tell them that you're looking for the sleep time and you can do a calculation of their total sleep time over total recording time.
- 50:08SPEAKER_09: Alternatively, they're wearing a wearable, use that wearable, and the insurances will utilize that in combination with a sleep diary.
- 50:14SPEAKER_09: So making sure you're taking advantage of the things that you have available to you.
- 50:19SPEAKER_09: Um and also because the MSLT tends to have a low sensitivity for patients with IH, you don't want to miss them just because the patient doesn't read the textbook.
- 50:28SPEAKER_09: So back to our patient.
- 50:30SPEAKER_09: Um Maggie, tell me a little bit about what your thoughts so far are on Elena.
- 50:36SPEAKER_09: Um, and then we're gonna continue on um to hear a little bit more from what our community and rural providers had to say.
- 50:45SPEAKER_06: So I think in her case, it's pretty typical of our patients.
- 50:48SPEAKER_06: It's taken her so long to even get to us, and she hasn't been asked the right questions.
- 50:52SPEAKER_06: So we really have to hone in and truly understand her story and what is her personal impact.
- 50:57SPEAKER_06: If we don't understand the person's impact, then we can't properly diag um, we can't properly understand how to treat them because it's not that one fits um all approach.
- 51:05SPEAKER_06: So really just honing in, and I mean it took her how many years before she even, you know, got to us that she's been struggling and um she's tried medicines that just didn't work.
- 51:14SPEAKER_06: So it is our job.
- 51:15SPEAKER_06: She's finally reached us, so let's give her the time of day and make her feel validated in the symptoms she is reporting so we can help her.
- 51:22SPEAKER_09: All right.
- 51:23SPEAKER_09: So let's hear from our first community rural KOL.
- 51:27SPEAKER_07: For case one, Helena Brooks.
- 51:31SPEAKER_07: My next step would be to refer directly for overnight PSG, next day, MSLT.
- 51:40SPEAKER_07: The clinical reasoning is because I believe there's enough information that doing any of the other options would really just be delaying what ultimately needs to take place, which is the sleep study.
- 52:02SPEAKER_07: While she could have depression and it's predominantly hypersomnia, it just doesn't seem to make sense because her PHQ is three.
- 52:17SPEAKER_07: I've never seen or heard of a patient who has overwhelming hypersomnia with virtually no depressive symptoms otherwise.
- 52:25SPEAKER_09: Alright, so um uh this is our our second community rural KOL.
- 52:30SPEAKER_03: For case one, Alina Brooks, my selection is administer the ESS, initiate a two-week sleep diary with activography, and reassess the symptom cluster, including prolonged sleep time, severe sleep inertia, unrefreshing naps, and brain fog.
- 52:47SPEAKER_03: My reasoning in my practice, my reflex with daytime sleepiness is to think OSA first.
- 52:54SPEAKER_03: But nothing here points that way.
- 52:56SPEAKER_03: She is young, there is no snoring, no witnessed apneas, no reflux, and the story is long sleep that does not refresh, brutal morning sleep inertia with multiple alarms, naps that do not help, and cognitive fog.
- 53:13SPEAKER_03: That cluster is not what my OSA patients describe.
- 53:17SPEAKER_03: Before I spend a specialist referral or order of study, the single most useful thing I can actually do from primary care is document how much she is truly sleeping and how sleepy she objectively is.
- 53:32SPEAKER_03: The diary plus ectigraphy tells me whether this is just insufficient sleep, which is rampant in graduate students.
- 53:40SPEAKER_03: And the ESS gives me a number to anchor on and track.
- 53:44SPEAKER_03: It also sets up any downstream sleep study to be valid because I know enough to remember that you cannot interpret an MSLT in someone who has been chronically sleep restricted.
- 53:57SPEAKER_03: So this option clarifies two of the three things the question is asking about and tees up the third correctly.
- 54:06SPEAKER_03: Why not the others?
- 54:08SPEAKER_03: The IHSS is not something I reach for in primary care, and as I understand it, it measures severity in someone you already think has IH rather than helping me sort IH from mood or insufficient sleep.
- 54:24SPEAKER_03: So it is premature here.
- 54:26SPEAKER_03: Let's hear from our next KOL.
- 54:29SPEAKER_05: My selection is administer the ESS, initiate a two-week sleep diary with actigraphy, and reassess the symptom cluster.
- 54:37SPEAKER_05: I'd start with what I can actually do in my office, an ESS and a sleep diary, to see whether she is truly getting enough sleep before I send her hours away for testing.
- 54:46SPEAKER_05: Her long, unrefreshing sleep and severe morning grogginess do not fit OSA, and she has already failed in antidepressants, so I would not send her back to psychiatry or just recheck three months.
- 54:58SPEAKER_05: I know enough to know that going straight to a sleep study needs some prep first.
- 55:03SPEAKER_09: So I think we covered a lot of the same kind of rationale, and again, just reinforcing that it's not necessarily that there's a single right answer, but making sure that the answer you're collecting is to really further inform um what exactly is going on.
- 55:20SPEAKER_09: So some um additional um uh community KOLs, as you can see here, we're seeing that there was the first one who said that I would admit one that said I would administer the IHSS, um, and then other two that had said that they would do the um upwards followed by all the sleep diaries.
- 55:39SPEAKER_09: So let's hear from um Karen Maskey and see what uh she had to say around this.
- 55:45SPEAKER_13: I would choose answer A, administering the upward sleepiness score, um, initiating a two-week sleep diary with actigraphy, and reassessing the symptom cluster, including prolonged sleep duration, sleep inertia, and unrefreshing naps, and brain fog.
- 56:02SPEAKER_13: I chose this because understanding the severity of the sleepiness using a validated instrument is very helpful.
- 56:11SPEAKER_13: Um, a two-week sleep diary, although this patient is very clear about their sleep timings, I do find it useful to kind of get habitual uh duration as described by objective testing with ectigraphy.
- 56:27SPEAKER_13: And also it's an opportunity if this patient is able to have unconstrained sleep to make a diagnosis of idiopathic hypersomnia based on ectigraphy, which could reduce the need to potentially come off of the SSRI that was recently started and do a PSG MSLT, as we are able to diagnose idiopathic hypersomnia by ectigraphy alone with a two-week period.
- 56:55SPEAKER_13: And reassessing the symptom cluster patient might actually meet the criteria for just someone who is a long sleeper.
- 57:03SPEAKER_13: Um, so I think that a reassessment could be potentially helpful before proceeding with other tests.
- 57:09SPEAKER_13: Um I didn't choose the answer B, administering the IHSS, because as it says it's a primary screening tool, it's really not.
- 57:19SPEAKER_13: It's you it's really a symptom severity scale.
- 57:23SPEAKER_13: Um and so it doesn't necessarily rule in or rule out, but it can be very helpful in identifying the severity of uh different domains of symptoms like the long sleep duration, sleep inertia, and the daytime sleepiness.
- 57:37SPEAKER_13: And again, it would be helpful to reassess symptoms with some sleep satiation before going directly to the PSG.
- 57:46SPEAKER_13: The patient's already been seen by psychiatry, so I didn't choose answer D without knowing how sleepy this patient is during the n during the day.
- 57:57SPEAKER_13: Potentially you could be sending this patient for testing and the multiple sleep latency test would be normal if they actually have relatively mild daytime sleepiness and what they're really complaining about fatigue.
- 58:10SPEAKER_13: So that potentially could make a prolonged uh journey for this patient and uh uh be a sort of a waste of resources.
- 58:19SPEAKER_09: So let's go across the pond to an EWA.
- 58:23SPEAKER_00: I will select the B because uh IHSS is exactly the questionnaire that fits the uh to the disease I do believe the lady is affected with.
- 58:33SPEAKER_00: So I will select the B.
- 58:35SPEAKER_00: I will not refer directly to a PhG to psychiatry, and I will not do directly PhG MSLT because I would prefer to try to stop CERTRINE.
- 58:46SPEAKER_00: I will not uh do sleep hygiene, I think it's out of scope of this lady.
- 58:51SPEAKER_00: And for ISS, yes, I will do SESS plus IHSS, and I will also certainly do sleep diarrhea, actigraphy, uh waiting for the PHG MSLT.
- 59:04SPEAKER_00: But the most important questionnaire for this disease, if I need to select just one, is IHSS.
- 59:10SPEAKER_00: So I will do some uh other assessment like diarrhea, actigraphy, and other questionnaire like ESS, but I will select the B.
- 59:20SPEAKER_00: So I S is a tool that will add uh, you know, some uh insight about sleepiness problem, long sleep duration problem during the night and during the day with the naps, and uh sleep inertia after adding the naps and adding the nighttime sleep.
- 59:39SPEAKER_00: So it helped a lot to quantify the complaint of the subject and not just excessively time sleepiness, which is assessed by ESS.
- 59:50SPEAKER_09: And last but not least, let's hear from John Carter.
- 59:54SPEAKER_04: I think probably the most accurate uh answer would actually be selection A, which is to administer the ESS, a two-week sleep diarrhea with activography, and then reassess.
- 1:00:03SPEAKER_04: The idea here is uh we want some objective data about the amount of time uh that the that the patient uh is sleeping.
- 1:00:11SPEAKER_04: She certainly describes uh long sleep times.
- 1:00:15SPEAKER_04: There's a slight difference between week night and weekend night uh sleep.
- 1:00:20SPEAKER_04: I would want to dig into that.
- 1:00:22SPEAKER_04: The patient seems like an act uh you know a good, accurate uh historian, but I've certainly been surprised uh many times in the past where the patient says they're sleeping 10 or 11 hours, but in fact they're sleeping four or five, so they end up uh with insufficient sleep.
- 1:00:37SPEAKER_04: So uh therefore I would say option A is going to be the best initial step to help help us differentiate uh between a uh CNS disorder of hypersonnolence, particularly IH, uh, and other potential mimicking conditions such as a primary mood disorder or insufficiency.
- 1:00:56SPEAKER_09: I think you get the story, right?
- 1:00:58SPEAKER_09: Of that there is some variation.
- 1:00:59SPEAKER_09: And I think that this becomes important because a lot of people become more secure in knowing that there is no one right answer.
- 1:01:07SPEAKER_09: It is a matter of responding to what the patient is describing and getting more of that data.
- 1:01:12SPEAKER_09: So now, as a part of this case-wise format, CME Outfitters also explored how an AI engine would approach the same clinical scenario using only the information presented in the case.
- 1:01:24SPEAKER_09: We asked OpenChat GPT 5.2, Dr.
- 1:01:30SPEAKER_09: So and so, um, what it would do next.
- 1:01:33SPEAKER_09: Um, and so the new chat here's the case's subjective, objective, and plan.
- 1:01:39SPEAKER_09: Uh, and essentially what it had stated was also A.
- 1:01:43SPEAKER_09: And so with that, the rationale is that the patient's history is highly suggestive of IH.
- 1:01:49SPEAKER_09: However, diagnose of IH requires uh documentation, which they are describing here.
- 1:01:54SPEAKER_09: Um, and as you can see, these are the ruleouts.
- 1:01:58SPEAKER_09: So again, going to the patient voice, I think this is um going to be important.
- 1:02:03SPEAKER_08: I think the primary area of where I would like to see change in the entire diagnostic process to get earlier diagnoses for individuals living with the experiences that I did is asking those deeper questions.
- 1:02:20SPEAKER_08: If someone is going to a clinician and saying, Oh, I'm I'm just feeling really tired, you know, instead of just ordering the blood panels and briefly going over sleep hygiene habits, of course, doing those things I think is essential and incredibly important to make sure everything else is okay.
- 1:02:36SPEAKER_08: But you know, when things come back, if they are normal, diving a little bit deeper, asking those deeper questions, how is this impacting your day-to-day life?
- 1:02:46SPEAKER_08: And really that area is the most important in my personal opinion.
- 1:02:55SPEAKER_08: What how is this impacting your daily life?
- 1:02:58SPEAKER_08: And if it is significantly impacting the way you're engaging and participating and showing up, if your quality of life feels different, that is definitely an area to help people identify, yes, that's what I'm experiencing, or maybe it really is a sleep paging issue.
- 1:03:16SPEAKER_08: It just asking those deeper questions to get to the root of what might be going on.
- 1:03:22SPEAKER_02: Let's hear from our next patient advocate.
- 1:03:26SPEAKER_12: Because I think there's so many people that that have some some kind of issue with their sleep, even if it's not a sleep disorder necessarily, there's something that could be improved.
- 1:03:39SPEAKER_12: Um so I think like that as a baseline that it should just be asked about.
- 1:03:46SPEAKER_12: And I think a part of that could be, you know, some kind of patient reported outcome measure.
- 1:03:54SPEAKER_12: Um but I think for me personally, like that's when like when I was handed that sheet of paper, I was like, oh, like everybody doesn't fall asleep in front of the TV, you know, or like like while driving, or you know, like all these other things.
- 1:04:10SPEAKER_12: And so that was like a real signal for me.
- 1:04:15SPEAKER_09: Now for last but not least, this was Becky who is um kind of feeling inflighted.
- 1:04:21SPEAKER_09: Uh let's see what she had to say.
- 1:04:24SPEAKER_11: I think what so one of the physicians she did a really great job of saying, Oh, interesting.
- 1:04:32SPEAKER_11: So tell me about this.
- 1:04:33SPEAKER_11: Tell me more about this.
- 1:04:35SPEAKER_11: She really tried to understand what the patterns were I was experiencing, seemed to be comparing those to kind of what is typical.
- 1:04:44SPEAKER_11: So let's go through kind of the motions of testing different things, you know, sleep apnea, home studies, things like that.
- 1:04:53SPEAKER_11: Um, the overnight sleep apnea studies, all of those kinds of things.
- 1:04:57SPEAKER_11: So I think what she got right with my symptoms was recognizing there is a pattern here of multiple things that are atypical.
- 1:05:06SPEAKER_11: And the patient is saying this is really becoming an issue for my life, my family, my children, my work.
- 1:05:15SPEAKER_09: All right.
- 1:05:16SPEAKER_09: So let's bring this together.
- 1:05:17SPEAKER_09: Um we have what our um video experts thought, what our learners thought, what we know from the data.
- 1:05:24SPEAKER_09: And so, in regards to some of these uh case perspectives and what you're seeing, is there anything else that either of you would add to this in regards to what we had just seen from the AI, the KOLs, or community rural clinicians?
- 1:05:41SPEAKER_01: I think that it reflects the fact that there isn't like a perfect answer to any of these things.
- 1:05:44SPEAKER_01: And clinical judgment is really, you know, there may be shades of gray sort of in the presentation or things that we didn't miss, but I think you can combine these things in an ideal world, right?
- 1:05:53SPEAKER_01: Like to Eve's point, I think he picked the IHSS because he likes to get it with the Epworth, right?
- 1:05:59SPEAKER_01: He mentioned that.
- 1:06:00SPEAKER_01: So I think it's important to remember that the F worth is very helpful, but it's a limited tool.
- 1:06:05SPEAKER_01: It just gets at one domain of functioning.
- 1:06:07SPEAKER_01: So wonderful.
- 1:06:10SPEAKER_09: So I think what we've learned from Ellen's case that the diagnostic delays have real costs that you can definitely see these red flags hiding in plain sight.
- 1:06:20SPEAKER_09: We even heard from our patients ask about sleep, then dig deeper.
- 1:06:24SPEAKER_09: I think that's the pattern, both from the responses that the clinicians and the KOLs had given, but also from our patients.
- 1:06:31SPEAKER_09: And that no single test is standing alone and making sure we're checking for confounders before testing.
- 1:06:37SPEAKER_09: So when we're looking at this, Maggie, why don't you take us through really kind of a practical framework that can be utilized?
- 1:06:45SPEAKER_06: So first we have to recognize that this patient has been struggling with this chronic disease for a while by the time they have reached us.
- 1:06:52SPEAKER_06: So we have to understand that it's at least more than three months, despite adequate sleep, long sleep time, severe sleep inertia.
- 1:06:59SPEAKER_06: We really need to hone in and we can't just ask the patient, do you have sleep inertia?
- 1:07:03SPEAKER_06: They're going to look at you and be like, what are you talking about?
- 1:07:06SPEAKER_06: We need to put that into terms that they understand, ask um specific questions.
- 1:07:10SPEAKER_06: How long does it take you to get functioning in the morning when your feet hit the ground?
- 1:07:14SPEAKER_06: You know, are you that one that you wake up but you are two, three hours into your morning before you actually feel like a human?
- 1:07:20SPEAKER_06: Are you get up and ready to go, but then it hits you 20 minutes later, you're ready to go back to bed.
- 1:07:24SPEAKER_06: So really understand what their morning feels like.
- 1:07:27SPEAKER_06: And then when you take naps, is it unrefreshing or do you feel a little spunk of energy?
- 1:07:31SPEAKER_06: Um, we need to go down and again get that symptom history.
- 1:07:34SPEAKER_06: Um use the ESS in addition to the hypersomnia severity screen.
- 1:07:39SPEAKER_06: Look at their mood, rule it out.
- 1:07:40SPEAKER_06: Is it also going on?
- 1:07:42SPEAKER_06: Is it heavily weighed on more mood than um sleep and and vice versa?
- 1:07:47SPEAKER_06: We have to exclude the mimics.
- 1:07:49SPEAKER_06: What are the things that could be leading us down the wrong path?
- 1:07:52SPEAKER_06: Just make sure we're not overlooking the obvious.
- 1:07:54SPEAKER_06: Make sure they are getting enough sleep.
- 1:07:56SPEAKER_06: Looking at are they getting quality sleep?
- 1:07:59SPEAKER_06: What could be fragmenting their sleep quality, rule out those breathing issues, rule out those movement issues?
- 1:08:04SPEAKER_06: Are they taking any medicines or substances that they may not think to totalists because it's not prescribed, um, that could be impacting what's happening in their sleep or even their daytime functioning.
- 1:08:14SPEAKER_06: Um, just because it is natural doesn't mean it's always the healthy thing.
- 1:08:18SPEAKER_06: Look at their circadian rhythm.
- 1:08:20SPEAKER_06: Super important.
- 1:08:21SPEAKER_06: We need to make sure that that patient is utilizing all 24 hours of the day and they're using it to the best of their ability.
- 1:08:26SPEAKER_06: Look at any medical and psychiatric issues.
- 1:08:30SPEAKER_06: And then we need to consider when and what is the appropriate testing for our patients.
- 1:08:34SPEAKER_06: And you know, nowadays we have to follow the guidelines of insurance.
- 1:08:38SPEAKER_06: When you have a patient with all these complaints, don't just stop at a home test and say, sorry, there's no problem, I don't see anything because your nighttime looks fine.
- 1:08:44SPEAKER_06: Dive deeper.
- 1:08:45SPEAKER_06: If the nighttime looks fine, you've rolled out everything.
- 1:08:48SPEAKER_06: Now it's time to move on to your day, your um overnight testing in the lab with your daytime um follow-up.
- 1:08:54SPEAKER_06: But at the same time, um, we were going back and forth of what should we do first.
- 1:08:58SPEAKER_06: And I think that question was posed a little heavily of we had to decide what to do first.
- 1:09:02SPEAKER_06: But nowadays, with the delays of even getting testing on the books, we can do it all together.
- 1:09:07SPEAKER_06: There shouldn't be a right or wrong answer.
- 1:09:09SPEAKER_06: Let's do it together because we know the final path we're going to.
- 1:09:11SPEAKER_06: So it's very important that we listen to the patient, validate the reasonings, and explain to them why we're doing it and what's the path we're going on.
- 1:09:19SPEAKER_06: So they're better understanding, hey, the pay the provider is on my side.
- 1:09:23SPEAKER_06: They're truly looking at me as a real human.
- 1:09:25SPEAKER_06: Um, and now I understand what we're gonna do and how we're gonna get there.
- 1:09:28SPEAKER_06: So now I really want to understand and explain to you guys when we keep going back to the ESS and the um idiopathic hypersomnia severity scale, why are we debating which one do we use?
- 1:09:39SPEAKER_06: I think we both we should use both, but let's understand the differences.
- 1:09:43SPEAKER_06: So when you're looking at the F-birth, it is really looking at what is the propensity to get drowsy or doze in the in normal everyday situations.
- 1:09:51SPEAKER_06: So how I ask my patients this is I'm gonna I tell them, I'm gonna put you in eight scenarios that are pretty boring.
- 1:09:57SPEAKER_06: And I want you to answer the question, how do you how does it impact your life in the middle of the day?
- 1:10:02SPEAKER_06: Not first thing in the morning, not late in the evening.
- 1:10:04SPEAKER_06: If I put you in this scenario in the middle of the day, would you get drowsy?
- 1:10:08SPEAKER_06: Not would you fall asleep, would you get drowsy?
- 1:10:11SPEAKER_06: And that's how we pose the questions.
- 1:10:13SPEAKER_06: Their answers are never, rarely, um, frequently, or always.
- 1:10:18SPEAKER_06: Um, so you're looking at um eight items, and then whenever the scores are between um zero and twenty four, twenty-four means they are more sleepy.
- 1:10:26SPEAKER_06: Um, the interpretation, anything greater than 10 suggests that yeah, this patient is really sleepy.
- 1:10:30SPEAKER_06: Um, it is um specifically looking at just all across the sleep disorders.
- 1:10:35SPEAKER_06: It is not very specific for IH, but it can tell us, hey, the patient is sleepy, maybe we need to dive a little bit deeper.
- 1:10:40SPEAKER_06: Um, we use this in according to um looking at treatment responsiveness.
- 1:10:45SPEAKER_06: Um, in our practice, we take it every single time the patient comes in the room to see us on every single visit.
- 1:10:50SPEAKER_06: And yes, they do get tired of taking it, and yes, we do get tired of interpreting it, but we do it because it helps us understand where they're going.
- 1:10:57SPEAKER_06: Um it does have, you know, it can depend on yesterday.
- 1:11:01SPEAKER_06: My score may have been a little bit lower, but today it's a little bit higher.
- 1:11:04SPEAKER_06: That helps us understand their story so we can peel it apart and say, why is it higher today?
- 1:11:09SPEAKER_06: What did you do different, or does this happen more often than we think?
- 1:11:13SPEAKER_06: Then of course it's a quick screen and we just can track it overall and look at patterns.
- 1:11:17SPEAKER_06: When we're looking at the idiopathic hypersomnia severity scale, um we're looking at the severity, frequency, and functional impact of the three core IH symptoms.
- 1:11:26SPEAKER_06: So it's more specific for IH.
- 1:11:27SPEAKER_06: That's your EDS and your naps.
- 1:11:29SPEAKER_06: Are you actually having to take them?
- 1:11:30SPEAKER_06: And what is the impact of your um daytime sleepiness?
- 1:11:33SPEAKER_06: Are you having prolonged, non-refreshable nighttime sleep?
- 1:11:35SPEAKER_06: And what is that sleep inertia?
- 1:11:37SPEAKER_06: Again, let's make sure we're losing the correct language.
- 1:11:40SPEAKER_06: It's 14 items and it's a total score from zero to 50.
- 1:11:43SPEAKER_06: Um, the higher the score discriminates untreated IH from controls.
- 1:11:48SPEAKER_06: So greater than 22, um, you're looking at a more impact and a more likelihood of IH.
- 1:11:54SPEAKER_06: Um, disease specificity, it is slated for IH.
- 1:11:58SPEAKER_06: So it doesn't just tell us our patient is sleepy, it has a higher indication, hey, this patient may have IH, we need to dive deeper and get to the correct testing.
- 1:12:05SPEAKER_06: Um it could be used for responsive of treatment once we start patients on treatment for an actual label of IH, and it helps us categorize the full symptom burden the patient is experiencing with IH.
- 1:12:16SPEAKER_09: So we're gonna go back um uh to talking to David for a moment, and if we can quickly go through, because I think you covered a lot of this already and has been covered.
- 1:12:26SPEAKER_09: Is there any other additional pieces that you would pull out of here to say this is how it differentiates IH from depression?
- 1:12:32SPEAKER_01: I think we have hit a lot of the high points.
- 1:12:33SPEAKER_01: I'd say it's one of the things that I sort of ask about, especially if someone has co-occurring depression, but you suspect IH, then it's even trickier, right?
- 1:12:42SPEAKER_01: So one of the things I think that's helpful is understanding the longitudinal history or progression.
- 1:12:47SPEAKER_01: So if people it's not uncommon for people to have depression and hypersonnolence present at the same time, but it's good to ask, well, when's the last time you were not depressed?
- 1:12:56SPEAKER_01: What was your sleep like then, right?
- 1:12:58SPEAKER_01: So if the sleepiness sort of never goes away or doesn't really get much better, that really tells you a lot.
- 1:13:03SPEAKER_01: Although keep in mind, sometimes when people's depression gets worse, their perception of how sleepy and how impaired they are can get worse as well.
- 1:13:09SPEAKER_01: But if they have periods of time where they're completely not depressed and they are still hypersomnolent, that is a big red flag in my mind.
- 1:13:15SPEAKER_01: Somebody might have IH.
- 1:13:17SPEAKER_01: And I think though that's probably the biggest thing of the things that we haven't talked about so far.
- 1:13:21SPEAKER_09: Wonderful.
- 1:13:22SPEAKER_09: So we're gonna throw it back to you guys and revisit this polling question.
- 1:13:27SPEAKER_09: See if based on the information that you just heard about, does your response change um to how you responded to this?
- 1:13:54SPEAKER_09: Um it looks like there was a little bit of movement here.
- 1:13:56SPEAKER_09: Again, I think that it it the exercise really is to help us just think through what is the information and how is it informing the situation.
- 1:14:04SPEAKER_09: Um so, in terms of another patient patient case, this is um uh Daniel Mercer, a 37-year-old guy, software engineer, referred for reevaluation after a prior assessment for presumptive OSA.
- 1:14:18SPEAKER_09: Uh, he's had symptoms that persisted for five to six years.
- 1:14:22SPEAKER_09: It's progressively um impacting him, never feeling fully awake, mental fog, difficulty sustaining attention, sleeping excessively, having a really hard time, not severe sleep inertia, requiring multiple alarms, daytime naps that are on more of the prolonged side, three to four times a week with no real restorative benefit.
- 1:14:42SPEAKER_09: Uh, and these symptoms now are interfering with his functionality, with work performance, daily functioning.
- 1:14:47SPEAKER_09: He wants to understand um what exactly is needed uh to clarify his issue.
- 1:14:52SPEAKER_09: He had a prior home test, no OSA.
- 1:14:55SPEAKER_09: Um, if you look at the picture, he doesn't really look like a guy phenotypically that we would expect to have OSA, no cranial facial, significant cranial facial disproportion, doesn't look like he has a micro gnanthea, retrognanthea, big neck, nothing like that.
- 1:15:07SPEAKER_09: Um and he um presents believing narcolepsy is likely after reading about it online.
- 1:15:14SPEAKER_09: And that's not in a common scenario either.
- 1:15:16SPEAKER_09: But there's no clear cataplexy as being described here, no paralysis, essentially no REM dissociative features, and the main symptom pattern remains long sleep time, severe morning sleep inertia, persistent fogginess, and non-restorative naps.
- 1:15:32SPEAKER_09: When we're looking at his medications and mood assessment uh screening, you're seeing very severe sleepiness with an 18 over 24.
- 1:15:42SPEAKER_09: And again, you're seeing this kind of feature of maybe some mild depression, maybe some minimal anxiety.
- 1:15:49SPEAKER_09: But again, these don't seem like these are the primary things that are describing.
- 1:15:53SPEAKER_09: I'd probably be pretty anxious too if I'm a software engineer and I'm sleeping all these hours, having a hard time getting to work, etc.
- 1:16:02SPEAKER_09: Uh, so based on this, what is the appropriate next step?
- 1:16:26SPEAKER_09: All right, so it looks like uh the majority would obtain a detailed current sleep uh history, document adequate sleep with a two-week sleep diary.
- 1:16:35SPEAKER_09: Um I don't know if either of you have any comments.
- 1:16:38SPEAKER_09: I think this is kind of similar to the prior conversations that we had.
- 1:16:41SPEAKER_09: Um uh so I do think that um uh that very well could be um accurate as well as if you were to borrow from the bottom of the upword slash IHSS, if that was the choice, that could potentially be an option.
- 1:16:54SPEAKER_09: So I do think that really any of these could be good next steps uh to keep you moving of what's going on.
- 1:17:00SPEAKER_02: Let's hear from our next KOL.
- 1:17:03SPEAKER_07: For case two, Daniel Mercer.
- 1:17:10SPEAKER_07: My recommendation would be proceed directly to overnight PSG followed by the next day MSLT.
- 1:17:17SPEAKER_07: I believe there's enough information at this point that it would only make sense to do that.
- 1:17:25SPEAKER_07: Patient has a significant ongoing history of hypersomulence, unrestful sleep.
- 1:17:36SPEAKER_07: Functional impairment due to the symptoms is evident.
- 1:17:39SPEAKER_03: Let's hear from our next KOL.
- 1:17:42SPEAKER_03: For case two, Daniel Mercer, my selection is obtain a detailed current symptom history, document adequate sleep with a two-week sleep diary and octigraphy, and perform an overnight PSG followed by next day MSLT.
- 1:17:58SPEAKER_03: My reasoning?
- 1:18:01SPEAKER_03: He has had years of symptoms, a severe ESS of 18, a prior negative home sleep apnea test, and a careful history that shows no cataplexy.
- 1:18:12SPEAKER_03: He came in convinced it is narcolepsy, but the picture he describes long sleep, severe morning inertia, unrefreshing nap, persistent fog, actually reads more like idiopathic hypersomnia than narcolepsy to me.
- 1:18:28SPEAKER_03: The right move is the complete, properly sequenced workup.
- 1:18:33SPEAKER_03: Confirm the history, document that he is genuinely getting enough sleep with the diary and octigraphy, and then get the overnight PSG with next day MSLT to settle narcolepsy versus IH and to make sure there is not residual OSA the home test missed.
- 1:18:53SPEAKER_03: Why not the others?
- 1:18:55SPEAKER_03: Going directly to PSG and MSLT skips documenting adequate sleep, which is the prerequisite that makes the MSLT valid, and skips closing out the history.
- 1:19:07SPEAKER_03: It is the same shortcut that risks an uninterpretable result.
- 1:19:13SPEAKER_03: Let's hear from our next KOL.
- 1:19:15SPEAKER_05: My selection is obtain a detailed current symptom history, document adequate sleep with a two-week sleep diary and actigraphy, and perform an overnight PSG, followed by next day MSLT.
- 1:19:28SPEAKER_05: He already had a negative home acne test and is still very sleepy.
- 1:19:32SPEAKER_05: So I would not let that be the end of it.
- 1:19:35SPEAKER_05: I would want the full workup done properly, confirm the history, and that he is sleeping enough, then the PSG and MSLT.
- 1:19:43SPEAKER_05: A questionnaire score alone would not give him an answer, and skipping the sleep documentation seems like it would undercut the testing.
- 1:19:50SPEAKER_09: So this is what they had responded with, with all giving um uh a similar response to what I think the audience had, of saying that uh they would obtain a detailed current uh symptom history, document adequate sleep with a two-week sleep diary, an ectigraphy, and perform an overnight polysonography, followed by uh next day MSLT.
- 1:20:11SPEAKER_09: Uh we're going to also uh take a listen to a little bit of each of the um KOLs to see what they have to say and then close it up with uh what ChatGPT had to say.
- 1:20:26SPEAKER_13: Um I would pick probably uh answer C, and this is only because I think it is a combination of next steps that would need to happen.
- 1:20:36SPEAKER_13: This patient is very sleepy and gives a pretty good history of his habitual sleep timings.
- 1:20:43SPEAKER_13: Um but again, I think for uh clinical practice guidelines do uh require a documented either sleep diary or preferably ectigraphy prior to testing.
- 1:20:57SPEAKER_13: Um so you know, this is something that you would want to make sure is done so that their interpretation of the overnight PSG and next day MSLT could be done appropriately.
- 1:21:09SPEAKER_13: This is a very sleepy individual who does not have sleep apnea based on HSAT testing.
- 1:21:16SPEAKER_13: And so uh the propensity to sleep during the day is high, and that plausibly the MSLT would be positive in this case.
- 1:21:25SPEAKER_13: Um we're oftentimes obviously making an evaluation for idiopathic hypersomnia, but the MSLT would also offer the opportunity to assess for narcolepsy symptoms and signs as well.
- 1:21:40SPEAKER_13: So even though he doesn't report more classic narcolepsy symptoms, remember the ICSD3 requires us to rule out narcolepsy.
- 1:21:50SPEAKER_13: So I did not pick um proceed directly answer A to the PSGM facility because the practice parameters do require the sleep diary or actigraphy.
- 1:22:03SPEAKER_13: I didn't select B just because I found it to be a little vague about what formal testing is pending, really.
- 1:22:11SPEAKER_13: Um and then D, the patient already has the eporth administered.
- 1:22:16SPEAKER_13: Um of course, validated hypersomnia questionnaires such as idiopathic hypersomnia scale will help us understand the severity, but it might not help us make a clear diagnosis without objective testing.
- 1:22:31SPEAKER_13: Again, the actigraphy or the PSG MSLT based on the ICSD criteria.
- 1:22:37SPEAKER_09: I think that we've been having this discussion of that this combination approach really is going to be very helpful.
- 1:22:45SPEAKER_09: Um let's see what Eve had to say.
- 1:22:47SPEAKER_00: Uh obtain a detailed current symptoms history, perform two weeks sleep diarrhea, ictography, and perform overnight PhD followed by next Eclipse MSLT.
- 1:22:58SPEAKER_00: I think that uh probably this is the best.
- 1:23:04SPEAKER_00: And uh because you will uh manage uh clinical history, questionnaire archigraphy, and the objective assessment.
- 1:23:13SPEAKER_00: We do have the SS already at 18 and validate the hypersomnia questionnaire and manage based on the score.
- 1:23:20SPEAKER_00: I I cannot select the D because the uh this questionnaire is not a questionnaire to diagnose to quantify the complaint.
- 1:23:29SPEAKER_00: So I will select the C because we need to confirm the diagnosis uh of IEH, which is probably the most uh probable diagnosis.
- 1:23:41SPEAKER_09: All right, and so here John Codder, he also is is saying the same thing.
- 1:23:46SPEAKER_04: So uh the standout uh answer for me is uh option C, uh, which actually kind of incorporates uh the elements of uh options number A and B.
- 1:23:58SPEAKER_04: Uh but I think here the the right next step is uh confirmatory diagnostic testing.
- 1:24:04SPEAKER_04: The patient is giving, again, a very clear uh history of symptoms consistent with IH, daytime sleepiness, functional impairment, uh adequate or long sleep times, unrefreshing uh naps, sleep inertia, uh, and uh no adjunctive um symptoms of narcolepsy, no cataplexy or REM intrusion uh phenomena.
- 1:24:27SPEAKER_04: Uh so it certainly sounds like it could be uh IH.
- 1:24:30SPEAKER_04: Again, this is a patient who's researched his his uh his symptoms, it sounds like.
- 1:24:35SPEAKER_04: Uh so it is important to uh do a good history uh and then uh as we are waiting uh for PSG and MSLT to confirm uh adequate sleep, ideally with actigraphy, uh if that's not possible at the very least uh with uh with a two-week uh sleep diary.
- 1:24:55SPEAKER_04: Uh and uh in that case, that I think would be the best option to point us in the right direction.
- 1:25:01SPEAKER_04: Um I think an important reference here uh is the uh the ICSD.
- 1:25:06SPEAKER_04: Again, the diagnostic criteria uh for IH include either a PSG or an MSLT or uh documentation of long sleep times uh via 24-hour PSG, which is not commonly done, or ectigraphy uh accompanied by sleep diary, which really should be done prior to the PSG and MSLT.
- 1:25:29SPEAKER_04: That's important because we want to rule out insufficient sleep or circadian rhythm issues or uh other non-central disorder of hypersonnolence factors as a potential etiology of the patient's symptoms.
- 1:25:45SPEAKER_09: So let's see what our chat GPT doc said.
- 1:25:48SPEAKER_09: And part of the rationale of utilizing this chat GPT is because this is what patients are coming in with now.
- 1:25:54SPEAKER_09: Um and in fact, this is what my residents are using to also tell me what they're gonna do next.
- 1:25:59SPEAKER_09: Um and so we wanted to really see is there is there a discrepancy here?
- 1:26:05SPEAKER_09: Um, and and what we're seeing is that it does look like they are um uh keeping up with the game.
- 1:26:10SPEAKER_09: They must have seen the CME before and fed it into this.
- 1:26:14SPEAKER_09: Uh they must have been using Notebook or some other model.
- 1:26:18SPEAKER_09: Uh and so it's good to know that we are having a consistency in regards to um what we should be doing next.
- 1:26:26SPEAKER_09: Um uh so do you any of you uh do either of you have any other additional comments in regards to what we've learned from Daniel's case?
- 1:26:33SPEAKER_09: Maggie, I'll throw it to you first.
- 1:26:35SPEAKER_06: Um no, it's just again, I keep stressing the negative HSD.
- 1:26:38SPEAKER_06: Um we we need to make sure that we're not um overlooking and just saying we're done here.
- 1:26:45SPEAKER_06: Um so I'm I'm very happy that we kept pushing forward to get them in the lab followed by the daytime test because what if the overnight study would have actually shown breathing issues or restless issues?
- 1:26:57SPEAKER_06: That's other things we have to treat in addition.
- 1:27:00SPEAKER_06: So we can't just always say, okay, the patient comes in with XYZ symptoms, and I'm gonna label them in my head as this, and that's the only path I'm gonna follow.
- 1:27:08SPEAKER_06: We need to make sure we're checking all of our boxes and truly questioning the patient every step of the way.
- 1:27:14SPEAKER_09: What about the fact of this five to six year delay?
- 1:27:17SPEAKER_09: He's a software engineer, he's in Palo Alto, he could have been the next founder, right?
- 1:27:22SPEAKER_09: Um and so there is these delays that we're not even thinking about of what did he have as his career goals and have that been impaired?
- 1:27:30SPEAKER_09: Many times we're looking at, well, you're st you're still fully employed, and so therefore, how disabled can you be?
- 1:27:36SPEAKER_09: And and I do think that that becomes really important to recognize that a person doesn't have to be um uh disabled to the point where they're not employed for them to have these diagnoses.
- 1:27:48SPEAKER_09: Do you have anything else to add, David?
- 1:27:49SPEAKER_01: The only thing I would add is I think in his description, he did say that he dreamed dreamed a lot, and so I might get a little bit I might ask a little bit more in the history about that and ask about things like dream enactment, which would tilt.
- 1:28:00SPEAKER_01: A little bit more towards the to a narcolepsy type of picture potentially for him because he is quite sleepy.
- 1:28:05SPEAKER_01: So just trying to make sure that you don't skip over the history in that particular context, I think it'd be helpful.
- 1:28:10SPEAKER_09: Yeah, I think that's a great point because in in my experience, um uh I tend to find that people who have idiopathic hypersomnia, they may not score as high as this.
- 1:28:20SPEAKER_09: They tend to sometimes even describe just like, I'm always having this hunger, but it's not like I'm gonna like just fall asleep out of nowhere.
- 1:28:27SPEAKER_09: Um, and so sometimes they do underestimate the severity of their sleepiness.
- 1:28:30SPEAKER_09: I agree with that.
- 1:28:31SPEAKER_06: And one more thing, I think it's important whenever we are questioning the patient that, you know, they're very quick to tell us how it's impacted their their work effort, right?
- 1:28:39SPEAKER_06: Because other people have brought it to their attention, they're not as productive, but we have to hone in and really question how has it affected their personal life?
- 1:28:46SPEAKER_06: Um, because they may be able to hold it together all day um to get their job done.
- 1:28:50SPEAKER_06: But what do they have left for their family?
- 1:28:51SPEAKER_06: What do they have left for their personal enjoyment that makes them feel human?
- 1:28:55SPEAKER_06: And so if we understand that from the beginning and we re-question that through the treatment process, are we giving them that full 24 hours back of their day?
- 1:29:03SPEAKER_09: Absolutely.
- 1:29:04SPEAKER_09: Uh so David, take me through very quickly um uh any of these potential mimics or causes and distinguishing features.
- 1:29:12SPEAKER_09: So provide us some high-level, like this is how you can use this information tomorrow in your clinic.
- 1:29:18SPEAKER_09: Not tomorrow, because you'll all still be here for a sleep conference.
- 1:29:20SPEAKER_09: The next day.
- 1:29:21SPEAKER_01: Well, and I think that Maggie hit on the fact that this, you know, you just you want to make sure sleep, not everybody has sleep apnea, right?
- 1:29:28SPEAKER_01: So keep that in mind that the negative tests you've got to keep going.
- 1:29:30SPEAKER_01: Um, and also you need to probably do an in-lab study.
- 1:29:32SPEAKER_01: But certainly sleep apnea can be a common cause of sleepiness, right, in the population.
- 1:29:36SPEAKER_01: So we do have to do some kind of evaluation for it.
- 1:29:38SPEAKER_01: Uh, insufficient sleep syndrome, we've already uh hit on the fact that you have to rule it out.
- 1:29:43SPEAKER_01: Actigraphy is usually the best way to do that, so it's oftentimes included in with the MSLT.
- 1:29:49SPEAKER_01: I think we haven't talked a lot about different medications that sometimes people can be on because in the case of vignettes, they really haven't had too many of those things.
- 1:29:56SPEAKER_01: But certainly we see patients on lots of medications, both prescribed and not prescribed.
- 1:30:01SPEAKER_01: You'd mentioned non-prescribed drugs like antihistamines, it can be sedating, especially um over-the-counter.
- 1:30:06SPEAKER_01: Uh but then and we've talked about benzodiazepines and things like that.
- 1:30:09SPEAKER_01: It's also important to keep in mind that uh sometimes people don't always tell us what they're taking, right?
- 1:30:13SPEAKER_01: So that's one of the reasons oftentimes if you're suspicious there might be drug use or something like that, people have that uh urine drug screen as part of the MSLT.
- 1:30:22SPEAKER_01: Uh and then uh the main point is like although idiopathic hypersonic is a diagnosis of exclusion, it doesn't mean that it can't be made, right?
- 1:30:28SPEAKER_01: And so it's important to sort of suspect it based on clinical phenotype, I think, and not just assume it's something else, uh, sort of the way I'd think about it.
- 1:30:38SPEAKER_09: All right, we're gonna throw it back to you guys and see um uh how your thoughts may have changed.
- 1:30:44SPEAKER_09: What would you do next?
- 1:31:05SPEAKER_09: All right, everyone agreed of uh put mostly of what they would do next in regards to um agreement with the uh KOLs and what the discussion has been.
- 1:31:15SPEAKER_09: Um uh let's just hear quickly from Haley and see what she has to say.
- 1:31:20SPEAKER_08: Regardless of the specialty of healthcare that you are in as a clinician, I feel that the most important area is recognizing the impact of daily life that each has on somebody and being open and vulnerable and uh trying to find ways that may not be one path, right?
- 1:31:46SPEAKER_08: There may be any any type of path that anybody can go through, but opening up those areas, seeing how as a patient I can I can figure out how to live life to the fullest and feel functional, feel fulfilled, that is the biggest area that I am very passionate about because AH is a very difficult diagnosis to live with, not because of the diagnosis itself, but the symptoms are are ever changing and they definitely have ups and downs throughout every stage of life that I've had so far, and it can take a toll on every aspect of health.
- 1:32:29SPEAKER_08: So making sure that the patient feels heard, that the patient feels seen, and that they feel prioritized really in how their life is looking and how that you may be able to provide something different is is an area that I think is essential to building into practice, especially working with individuals with IH.
- 1:32:55SPEAKER_02: Let's hear from our next patient advocate.
- 1:32:59SPEAKER_12: I think the main thing, you know, especially with IH specifically, is everybody experiences it so differently.
- 1:33:08SPEAKER_12: And so I think it's important to just listen, like literally just stop and listen to what what this person is telling you and and how it impacts their life.
- 1:33:23SPEAKER_12: If there's any like researchers listening, I know a lot more people are talking about sleep and um are doing a lot of research on on new medications and things that may be able to help.
- 1:33:38SPEAKER_09: So if I were to summarize what we just heard from patients, I didn't hear either of them say, please make sure you measure me as Epward Sleepiness scale and not even idiopathic hypersomnia severity scale.
- 1:33:47SPEAKER_09: And so remembering that these validated scales are great for research.
- 1:33:52SPEAKER_09: However, they do not reflect the human-lived experience.
- 1:33:54SPEAKER_09: What you did hear from these patients is ask me about the functional impact in my life, how I'm not able to show up the way that I want to be.
- 1:34:04SPEAKER_09: I always share when I'm talking to my residents and very frequently when I'm speaking on this, the most important question I ask any of my patients is, what can't you do because of your diagnosis?
- 1:34:16SPEAKER_09: Why is this the most important question?
- 1:34:18SPEAKER_09: Is because that now becomes our treatment goal, because the first thing they say is clearly the highest priority.
- 1:34:25SPEAKER_09: What you heard Caitlin say was describing what goal setting and goal attainment is.
- 1:34:33SPEAKER_09: That should be our priority at every single visit.
- 1:34:36SPEAKER_09: The validated skills help facilitate the ease of the prior authorization, but not the ease of living with this condition.
- 1:34:44SPEAKER_09: And so I think that becomes a really important point if you take home nothing else.
- 1:34:49SPEAKER_09: The other part that Caitlin shared is thank you for doing the research and for there being emerging medications that may help more individuals.
- 1:34:59SPEAKER_09: And this is where we're going to see the future of the landscape of more oxabates, the erxinergic medications, and then potentially some histaminergic agents as well.
- 1:35:09SPEAKER_09: So when you're talking about this and we're closing the case, we want to turn complexity into clarity in IH care.
- 1:35:16SPEAKER_09: And I hope that we shined a little bit of light into that today.
- 1:35:19SPEAKER_09: IH care demands earlier recognition, accurate diagnosis, and a readiness for an evolving treatment landscape.
- 1:35:28SPEAKER_09: We can't treat every single person with a singular medication.
- 1:35:32SPEAKER_09: However, we can singularly treat every single person maximally if we actually listen to what they say that they need.
- 1:35:42SPEAKER_09: So diagnostic delays impose not just an inconvenience, but it's a measurable and preventable burden.
- 1:35:48SPEAKER_09: It comes in a variety of different ways, including shaping their self-identity as well as even a deconditioning of recognizing the symptoms they're experiencing.
- 1:35:58SPEAKER_09: We have the ICSD3TR criteria, which is a starting point.
- 1:36:02SPEAKER_09: It's important, it's not the finish line.
- 1:36:04SPEAKER_09: Patients don't read the textbook, and we recognize that these criteria still are lacking in being able to identify all of our patients.
- 1:36:12SPEAKER_09: And because of this expanding pipeline, it makes getting the diagnosis right more consequential than ever and making sure that when you are utilizing medications, even if you already achieved a diagnosis that you think the patient has, use that therapeutic response as the opportunity to second guess, did I make the right diagnosis?
- 1:36:34SPEAKER_09: Your patient won't be mad.
- 1:36:35SPEAKER_09: Are you questioning the diagnosis if you think that you have a better one that may actually fit them and help them?
- 1:36:41SPEAKER_09: They'll be relieved and thankful that you've listened and you paid attention and you're acknowledging the feedback that they're giving them.
- 1:36:48SPEAKER_09: Um so it it does become, I think, a really important piece.
- 1:36:51SPEAKER_09: With that, I would ask David and and Maggie, do you have any other um brief comments that you would like to say?
- 1:36:58SPEAKER_01: I mean, I guess the only thing that I would say is keep an open mind, you know, when you're talking to patients and try to ask a little bit more about what their life is like, um, because you'd be surprised at what they'll tell you.
- 1:37:07SPEAKER_01: Uh, and it can be really helpful in terms of um really moving the needle forward for people, I think, in the long term.
- 1:37:13SPEAKER_06: And I would just add, um, whenever the patient is under the major symptomatic um issues of the disease state, um, and you ask them what is their goal that they want to do, once you achieve that goal, ask them what's their next one.
- 1:37:27SPEAKER_06: They may have net set may have not set their highest goal from the beginning because they never thought they can get there.
- 1:37:32SPEAKER_06: So let's keep encouraging them and working with them to understand how they can be their best, not my best, their best, because the goals are never gonna stop and we shouldn't be limiting them to that.
- 1:37:43SPEAKER_09: Wonderful.
- 1:37:44SPEAKER_09: Before I do a couple of the closing slides, you guys were great in sending in questions.
- 1:37:48SPEAKER_09: So I'm gonna just summarize a couple of the ones that had come in because you clearly were paying attention, you clearly were asking questions.
- 1:37:55SPEAKER_09: Uh so a couple of them were um, do you both do you get both the ESS and IHS at every visit?
- 1:38:02SPEAKER_09: Um uh I will say that I do not.
- 1:38:05SPEAKER_09: Um what about you guys?
- 1:38:07SPEAKER_01: I certainly get the airport at every visit, the IHSS.
- 1:38:10SPEAKER_01: I sort of tend to use again when I think that I someone might have IH.
- 1:38:14SPEAKER_01: I don't use it sort of across the board because I think, again, it may not be applicable to a lot of disorders.
- 1:38:20SPEAKER_09: Sure.
- 1:38:20SPEAKER_09: Maggie, any comments?
- 1:38:21SPEAKER_06: I do the ESS at every visit.
- 1:38:23SPEAKER_06: The IH is just as needed.
- 1:38:25SPEAKER_09: Wonderful.
- 1:38:26SPEAKER_09: And then um in regards to the sleep testing, do you really need I'm gonna kind of combine a couple of them and then you guys can tell me what your thoughts are.
- 1:38:34SPEAKER_09: Do you really need the PhD MSLT if the sleep diarrhea and ectigraphy demonstrate total sleep time more than 12 hours?
- 1:38:40SPEAKER_09: Um.
- 1:38:41SPEAKER_09: Um uh HST for 24 hours, maybe if it has an EEG, a home sleep test?
- 1:38:48SPEAKER_01: I don't think that there are enough validated pathways for doing that.
- 1:38:51SPEAKER_01: That is an open question.
- 1:38:52SPEAKER_01: And I think in the future we'll be using more ambulatory technologies to show long sleep duration.
- 1:38:56SPEAKER_01: But now I think it depends on the technology.
- 1:38:59SPEAKER_01: Battery life is a big issue with a lot of the portable units that are available now.
- 1:39:03SPEAKER_09: Yeah, that's when I'll just go with the ambulatory EEG.
- 1:39:06SPEAKER_09: Um uh instead of activity, what about wearables?
- 1:39:09SPEAKER_09: Absolutely.
- 1:39:09SPEAKER_09: The insurance will accept them.
- 1:39:11SPEAKER_09: Um I get the downloads, I upload them the same as I would in ectigraphy.
- 1:39:15SPEAKER_09: They do accept them for treatment.
- 1:39:16SPEAKER_09: Just make sure you're doing them with the sleep diaries.
- 1:39:18SPEAKER_09: Big limitation is they don't pick up naps.
- 1:39:20SPEAKER_09: So you do need to have those documented by your by your patient.
- 1:39:24SPEAKER_09: Um how do you get ectigraphy covered?
- 1:39:27SPEAKER_09: You don't, it's charity.
- 1:39:29SPEAKER_09: Um, most insurance deny, which is why you use the wearables.
- 1:39:32SPEAKER_09: Um and so one other one that came in is um can you please comment on pursuing a diagnosis of of uh possible IH in an older patient or residual excessive daytime sleepiness after adequate OSA?
- 1:39:46SPEAKER_09: First, I'll just say yes, you should.
- 1:39:48SPEAKER_09: Um Is there any specific things that you would call out other than if whatever the treatment they're using, use that with the PSG M SLT to make sure that you're not getting rebound or anything else?
- 1:39:58SPEAKER_01: Well, I would say if a patient presents older um than the cases that we had, it can be more challenging because there are going to be more medications, more medical comorbidities, other things happening.
- 1:40:08SPEAKER_01: I think in that case, history is really key.
- 1:40:11SPEAKER_01: I I think if someone presents with you know nuance at daytime sleepiness in their 60s, that's potentially different.
- 1:40:18SPEAKER_01: I mean it could be IH, but you have to think about other things at play as well.
- 1:40:22SPEAKER_01: So if but if they said, look, I've had this problem since I was a teenager, right, and never went away or I never came to treatment, I think that's really important in sort of trying to tease things apart.
- 1:40:35SPEAKER_06: Um because as we get older, even the younger ones, we are just sitting in front of the TV vegging out, gonna feel more tired, and that's where the depressive symptoms, you know, start to be questioned.
- 1:40:46SPEAKER_06: So ask where they're actually getting up and doing things, and then that's where they get tired, or are we just not activating anything and then our our sleep is messed up after that too?
- 1:40:55SPEAKER_06: So ask about activity level.
- 1:40:59SPEAKER_09: Um and I'm gonna do two more, and then the two that I actually am going to do is is ones that I I commonly encounter.
- 1:41:07SPEAKER_09: One is what do you think about the overlaps between uh chronic fatigue syndrome, long COVID?
- 1:41:13SPEAKER_09: Should all these patients also have a PSG MSLT?
- 1:41:19SPEAKER_01: So it's a tricky question.
- 1:41:20SPEAKER_01: What I would say is if you suspect a sleep disorder, it makes sense to get a PSG MSLT.
- 1:41:25SPEAKER_01: If you're not sure sort of what to do, a PSG MSLT is a it's a it captures a lot of information, right?
- 1:41:32SPEAKER_01: It'll give you a lot of data about whether people have because those folks may also have a cold sleep disorder breathing, they may have a lot of other things in place.
- 1:41:39SPEAKER_01: I wouldn't indiscriminately use the PSG MSLT though, because you have to keep in mind, even if you take people off the street, they can have abnormal PSG MSLTs, right?
- 1:41:49SPEAKER_01: So you always have to combine the PSG with sort of your clinical acumen to sort of decide whether the right plan.
- 1:41:55SPEAKER_06: And on that note, I'm gonna take it to the flip side.
- 1:41:57SPEAKER_06: If you have a patient that the um NPHG MSLT doesn't answer their cause, and it's more on the negative side, but you're like this patient, that the data doesn't match, continue to retest because they may have just had a really bad testing day.
- 1:42:12SPEAKER_06: Um, there may have been some environmental situation going on that was out of our control.
- 1:42:17SPEAKER_06: So if you truly feel the patient is symptomatic and the test did not validate that, continue to test and push forward.
- 1:42:23SPEAKER_09: I'll put a pitch into CMEO for uh a CME on COVID and hypersomnolence disorders.
- 1:42:29SPEAKER_09: Um, both the vaccine as well as COVID can be associated with the development of hypersomnolence.
- 1:42:35SPEAKER_09: Um, and they tend to be more of an IH phenotype than they are a narcolepsy phenotype.
- 1:42:39SPEAKER_09: We also see this as like a compounding effect, individuals who had a history that looked maybe like a narcolepsy and then um develop more of this IH phenotype, uh, and they typically have very, very severe disodautonomia symptoms.
- 1:42:52SPEAKER_09: Um so I think this is an area of exploration, but one that very well could be uh a CME on its own.
- 1:42:58SPEAKER_09: Um and then uh last but not least, if a patient is quite functional by self-medicating with caffeine, would you do anything differently?
- 1:43:11SPEAKER_01: I guess it depends on if they have like AFib or something.
- 1:43:14SPEAKER_01: I mean, so it if people are doing well, they probably usually aren't coming to you, I guess is the way that I would think about it.
- 1:43:21SPEAKER_01: So they may be if they it must be either disturbed by the amount of caffeine that they're taking.
- 1:43:26SPEAKER_01: But certainly there are people out in the world who probably have IH that aren't coming to the clinic and are and are managing.
- 1:43:32SPEAKER_01: And the the reality is there may be better ways to manage their symptoms than caffeine.
- 1:43:37SPEAKER_01: Like, so I I think that would be worth exploring with people, right?
- 1:43:40SPEAKER_01: Like, do you want to keep taking this amount of caffeine and is it doing what you really need to do?
- 1:43:44SPEAKER_01: Because a lot of times people take caffeine and they feel kind of wired, right?
- 1:43:47SPEAKER_01: And then but it often it also wears off too.
- 1:43:49SPEAKER_01: And I think we had a clinical vignette that we talked about.
- 1:43:52SPEAKER_01: I think most patients with IH, if they try to use caffeine, a lot of them are actually kind of give it up because they're like, it doesn't work.
- 1:43:58SPEAKER_01: So I just I just don't use it.
- 1:44:00SPEAKER_09: Yeah.
- 1:44:01SPEAKER_09: I think the key question is what are they defining as functional?
- 1:44:04SPEAKER_09: And sometimes they've already imposed the glass ceiling.
- 1:44:07SPEAKER_09: Um and so really looking at all those spheres of wellness to see where they can actually do better.
- 1:44:12SPEAKER_09: Um and I would say that that's a whole lot of caffeine you have to keep redosing throughout the day.
- 1:44:17SPEAKER_09: Um so they're poor bladder.
- 1:44:19SPEAKER_09: Um, and so we do have better options.
- 1:44:22SPEAKER_09: And so I would say that I would I would do an alternative.
- 1:44:25SPEAKER_09: And I have seen clinicians actually prescribe caffeine and say that this is better, you're not that bad.
- 1:44:31SPEAKER_09: You don't need a prescribed medication.
- 1:44:33SPEAKER_09: Um and so I do think that that is a good thing to address.
- 1:44:37SPEAKER_09: I want to thank both of you, David and Maggie, for um participating in this and all of your insights as we navigated through these diagnostic challenges and solutions.
- 1:44:47SPEAKER_09: I do want to review our SMART goals from today.
- 1:44:50SPEAKER_09: And so um, with our SMART goals, is it specific, measurable, achievable, relevant, and time limited.
- 1:44:56SPEAKER_09: And so this is how you put information into action.
- 1:44:59SPEAKER_09: So these are your key takeaways.
- 1:45:01SPEAKER_09: Improve clinician confidence in differentiating IH from depression, mood disorders, NT2, OSA, and insufficient sleep syndrome when evaluating chronic EDS.
- 1:45:12SPEAKER_09: We're gonna want to increase the proportion of patients with suspected IH to receive a guideline concordant workup, uh structured symptom history, validated scales, increase the use of validated patient-reported measures such as the IHSS and F worth to characterize the sleep inertia, long sleep time, unrefreshing naps, the diagnosis and to track treatment response over time.
- 1:45:33SPEAKER_09: Um and then finally reduce diagnostic delay by reassessing, and hopefully, in more than 50%, um, more patients uh carrying a presumptive depression or NT2 label for underlying central disorder of hypersomnence when symptoms persist despite treatment.
- 1:45:50SPEAKER_09: For additional resources, you are gonna want to visit the CME Outfitters uh website.
- 1:45:55SPEAKER_09: They have great clinical information and certified educational activities.
- 1:46:01SPEAKER_09: And of course, you want to make sure you're visiting the Sleep Disorders Hub, which can also be found on the CME Outfitters for free resources in education, educate healthcare professionals as well as patients.
- 1:46:11SPEAKER_09: And don't forget about the Hypersomnia Foundation either, which you can, of course, scan this QR code to learn more and access additional resources.
- 1:46:22SPEAKER_09: Uh, these I really would say they really do have some great tool kits.
- 1:46:26SPEAKER_09: And thank you guys so much for your participation.
- 1:46:28SPEAKER_09: You really were quite active and engaged.